

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Relationship between *Helicobacter pylori* infection and risk of osteoporosis: A systematic review and meta-analysis

| | |
|-------------------------------|--|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2018-027356 |
| Article Type: | Research |
| Date Submitted by the Author: | 18-Oct-2018 |
| Complete List of Authors: | Wang, Taiwu; Third Military Medical University, Department of Epidemiology Li, Xiang; The Southwest Medical University, School of pharmacy Zhang, Qi; Research Institute for Medicine of Nanjing Command Yu, Lei; Third Military Medical University, Department of Epidemiology Cai, Tongjian; Third Military Medical University, Department of Epidemiology Zhang, Yao Xiong, Hongyan |
| Keywords: | osteoporosis, bone mineral density, <i>Helicobacter pylori</i> , meta-analysis |
| | |

SCHOLARONE™
Manuscripts

Original article

Relationship between *Helicobacter pylori* infection and risk of osteoporosis: A systematic review and meta-analysis

Running Title: Relationship between *H. pylori* and osteoporosis

Taiwu Wang^{1,2,*}, Xiang Li^{3,*}, Qi Zhang², Lei Yu¹, Tongjian Cai¹, Yao Zhang^{1,†}, Hongyan Xiong^{1,†}

¹ Department of Epidemiology, College of Preventive Medicine, Third Military Medical University, Chongqing 400038, People's Republic of China.

² Research Institute for Medicine of Nanjing Command, Nanjing 210002, P. R. China.
293 Zhongshan Eastern Road, Nanjing, 210002, People's Republic of China.

³ School of pharmacy, The Southwest Medical University, Luzhou 646000, People's Republic of China.

* These authors contributed equally to this work.

† These authors jointly supervised this work.

Corresponding author's information: Hongyan Xiong,

Address: Gaotanyan Road 30, Shapingba District, Chongqing 400038, China,

E-mail: hongyanxiong@126.com,

Tel: +86-023-687752295.

Word count: 3003

Abstract

Objective Many studies have explored the association between *Helicobacter pylori* (*H. pylori*) infection and osteoporosis. However, evidence on *H. pylori* infection and risk of osteoporosis is still controversial. Therefore, we performed this systematic review and meta-analysis to evaluate the association between *H. pylori* infection and osteoporosis.

Design Systematic review and meta-analysis of case-control study.

Participants People with or without osteoporosis.

Data sources A comprehensive literature search was performed on PubMed, Embase, Web of Science and CBM for studies investigating the association between *Helicobacter pylori* infection and osteoporosis up to April 30, 2018. English and Chinese languages papers were considered. Two independent investigators selected studies. The methodological quality of the studies was assessed using the Newcastle–Ottawa scale.

Main outcomes and measures Pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated using random effects model if heterogeneity existed, otherwise using fixed effects model was used. Subgroup analyses were also performed to explore source of the heterogeneity. Sensitivity analyses and publication bias were also tested.

Results A total of 21 studies with 9655 participants were included in our analyses. Taking together, we found that *H. pylori* infection was significantly associated with increased risk of osteoporosis (OR (95%CI), 1.39(1.13–1.71)); there was no significant difference between osteoporosis and osteopenia; males had relatively higher risk than females. However, the decrease of bone mineral density in *H. pylori* positive patients was

1
2
3
4 not significant compared with *H. pylori* negative controls, which may due to the sample
5
6 size.
7

8
9 **Conclusion** Our meta-analysis suggests a significant increased risk of osteoporosis in
10 patients with *H. pylori* infection. The clinicians should pay more attention to the patients
11 infected with *H. pylori*. Further researches are needed to confirm these findings and to
12 identify the underlying biological mechanisms and confounding factors, and to detect the
13 influence of variables across studies.
14
15
16
17
18
19
20

21
22 **Keywords:** osteoporosis; bone mineral density; Helicobacter pylori; meta-analysis.
23
24
25
26
27
28
29

30 **Strengths and limitations of this study**

- 31
32
33 ▶ We explored the association between osteoporosis and Helicobacter pylori, and found a
34 positive result which is different from the previous one and more comprehensive.
35
36
37 ▶ The number and quality of studies included is limited. Therefore, the results of the
38 meta-analysis should be interpreted with caution.
39
40
41
42
43 ▶ Causality can't be established in observational study.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Helicobacter pylori (*H. pylori*), a Gram-negative and spiral-shaped bacterium dwelling on the gastric epithelium, has an influence on approximately 50% of the global population, especially those living in developing countries¹. The prevalence of *H. pylori* infection is approximately 30% in developed countries and up to 80% in developing countries^{2,3}, and up to 90% in patients with dyspepsia⁴. In north Europe and North America, about one-third of adults are infected, and in south and east Europe, South America, and Asia, the prevalence of *H. pylori* is often higher than 50%⁵. Moreover, infected subjects born abroad (first-generation immigrants) had a higher risk of *H. pylori* infection than second-generation immigrants in a multi-ethnic European city⁶. Compared with high prevalence, the low spontaneous eradication rate of *H. pylori* infection makes the situation more serious. For example, the spontaneous eradication rate is only 2.9% over the one-year period among schoolchildren aged 7-12 years⁷. *H. pylori* has been well-known to associated with gastrointestinal diseases, such as gastritis, gastric ulcer, stomach cancer and so on⁸. However, many non-gastrointestinal diseases may also have associations with *H. pylori*, some of them have been proven by large-scale population researches or meta-analysis, such as preeclampsia⁹, autoimmune thyroid diseases¹⁰, myocardial infarction¹¹, hepatic encephalopathy¹² and prostatitis¹³.

Osteoporosis is one of the most common metabolic bone diseases, characterized by decreased bone mineral density (BMD), increased bone fragility, and then increased susceptibility to fracture¹⁴, especially in spine and hip. Osteoporosis has become a major

1
2
3
4 health concern for both individuals and societies. Osteoporosis has huge adverse impact
5
6 on life quality and is associated with increased morbidity rate. The in-hospital mortality
7
8 rate is also up to between 0.85 to 2.26%¹⁵. In Europe, about half of women and one-fifth
9
10 of men aged over fifty years develop pathological hip, spine, forearm, or humerus
11
12 fracture due to osteoporosis during their remaining lifetime¹⁶. The same situation happens
13
14 in other countries or district, such as Japan^{17 18} and Taiwan.

15
16
17
18
19 There are well established evidence regarding the risk factors for osteoporosis ¹⁸, such as
20
21 age, sex, body mass index (BMI), alcohol, and smoking. *H. pylori* infection can induce
22
23 individual inflammatory and immune reactions, such as the increased releasing of IL-1
24
25 and TNF- α , which could trigger bone resorption, and regulate bone turnover¹⁹. Recently,
26
27 many studies about the association between osteoporosis and *H. pylori* have been
28
29 performed. However, the role of *H. pylori* in osteoporosis remains controversial. This
30
31 issue has been discussed in previous meta-analysis ^{20 21}, but no significant association
32
33 was found. As more studies evaluating the association between *H. pylori* infection and
34
35 osteoporosis have been published since then ^{2 22-28}, we carried out this updated
36
37 meta-analysis to further evaluate the association between *H. pylori* infection and
38
39 osteoporosis qualitatively, and the quantitative alterations of BMD in *H. pylori* infected
40
41 patients compared with those in healthy controls.
42
43
44
45
46
47
48
49
50
51
52

53 **Materials and Methods**

54
55
56 This study was performed based on Preferred Reporting Items for Systematic Reviews
57
58
59
60

(PRISM) checklist ²⁹ for systematic review and meta-analysis. Study searching and selection, quality assessment, and data extraction were done by two researchers independently to avoid bias.

Search strategy

We searched through the databases of PubMed, EMBASE, Web of Science and Chinese Biomedical Literature Database (CBM). The last search for all databases was updated to April 30, 2018. We used the combined method of MeSH Term and free words by applying the following terms: *Helicobacter pylori*, *campylobacter pylori*, *H. pylori*, *hp*, *helicobacter*, *helicobacter bill*, *helicobacter hepaticus*, *helicobacter pullorum*, *helicobacter species*, *helicobacter sp*, *helicobacter genus*, *campylobacter*, *campylobacter infection*, *campylobacteriosis*, *Helicobacter pylori infection*, *Helicobacter infection*, *pylori*, *enterohepatic helicobacter spp*, *campylobacter sp* and fragility fracture, bone density, bone mass density, osteocalcin, bone loss, osteoporosis. Two authors evaluated potential publications by checking their titles and abstracts and then procured the most relevant publications for a closer examination. Bibliographies section of retrieved articles were also reviewed for additional pertinent studies which were possibly missed in the initial search.

Studies selection and data Extraction

Studies were included if they met the following criteria: (1) it is an observational study; (2) its objective of interest is to assess the association between *H. pylori* infection and osteoporosis; (3) they either provided risk estimates with odds ratios (ORs) and 95%

1
2
3
4 confidence intervals (95% CIs), or sufficient information was available to calculate the
5
6 ORs and 95% CIs. Articles were excluded if they were duplicate publications, reviews,
7
8 animal studies, editorials, and case reports. The papers were also excluded if no effect
9
10 estimate was reported or no enough raw data for ORs and 95% CIs calculation. In the case
11
12 of multiple studies with the same or overlapping data published by the same researchers,
13
14 we selected the most recent study with the largest number of participants. All papers
15
16 meeting the criteria defined above were included for further analysis.
17
18
19
20
21

22 The literatures included were carefully reviewed for information about the first author,
23
24 publication year, country, population, sample size, sex, age, detection methods of *H.*
25
26 *pylori* and osteoporosis, diagnosis location, diagnosis, and adjusted covariates.
27
28
29

30 If data could be acquired from the tabulated literature search results, they would be
31
32 extracted carefully into 2x2 tables from all eligible publications by two independent
33
34 reviewers. If data were not directly available, they would be calculated from published
35
36 positive predictive values and/or negative predictive values if appropriate. The adjusted
37
38 OR (95% CI), if existed, was adopted instead of crude OR (95% CI). Two researchers
39
40 conducted data extraction independently. A third researcher was consulted when there
41
42 were discrepancies in the data, and agreement was reached after discussion.
43
44
45
46
47

48 **Quality assessment**

49
50 Quality assessment was performed using the Newcastle-Ottawa quality assessment scale
51
52
53³⁰. Two researchers conducted blinded quality assessment of the included literatures. The
54
55 NOS assigns a maximum of 9 points to studies of highest quality according to three
56
57
58
59
60

1
2
3
4 quality parameters: selection, comparability, and outcome. When the researchers'
5
6 assessments were discrepant, a third researcher was consulted for the final grading.
7
8

9 **Statistical analyses**

10
11 The primary measures were ORs and 95% CIs for the association between *H. pylori* and
12
13 osteoporosis, and standardized mean difference (SMD) for BMD alterations between *H.*
14
15 *pylori* infected patients and healthy controls. To assess heterogeneity among the studies,
16
17 we calculated the Cochran's Chi-squared test (with $p < 0.10$ indicating statistically
18
19 significant heterogeneity) and the statistic I^2 ³¹ (The heterogeneity might not be important
20
21 with I^2 of 0 to 40%, while moderate heterogeneity with I^2 of 30 to 60%, substantial
22
23 heterogeneity with I^2 of 50 to 90% and considerable heterogeneity with I^2 of 75 to 100%).
24
25
26
27
28

29
30 The pooled results were calculated using fixed effects model if no obvious heterogeneity
31
32 existed, otherwise random effects model was used. The cumulative meta-analysis was
33
34 conducted for the extracted data using a pooled random effects model with the
35
36 publication year. In the event of obvious heterogeneity, subgroup analysis was performed
37
38 according to sex, diagnosis method and locations of osteoporosis, and detection method
39
40 of *H. pylori*. Meta regression was also performed to explore the potential heterogeneity.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Publication bias was assessed by funnel plot and Egger's test (Egger's test was done only
if the studies number was no less than 10)³¹. All statistical analyses were performed
using Stata 12.0.

56 **Results**

Search results

Using our search criteria, a total of 1720 articles were identified through PubMed, Web of Science, Embase and CBM, and one additional record identified through other sources. Then, 443 duplicate papers were removed firstly, and 1242 papers were excluded after scanning their titles and abstracts. After screening the full texts of the included articles, 15 studies were excluded for the following reasons: duplicate publication(n=4), not about the topic(n=2), no related data about *H. pylori* and/or osteoporosis(n=4), lack of access to full text (n=5). A total of 21 studies^{2 17 22-28 32-43} were included for further analysis (Fig. 1).

Study Characteristics

A total of 21 articles were included in this study. Of them, 20 provided data for association between *H. pylori* and osteoporosis^{2 17 22-28 32-40 42 43}, 4 for the BMD alterations in *H. pylori* positive patients compared with healthy controls^{24 33 34 41}, 3 provided both^{24 33 34}. All these studies were published from 2005 to 2018. Four studies were conducted in China, 3 in Iran, 2 in Italy, 9 in Japan, 1 in Brazil, 1 in Korea and 1 in Turkey. As to the sex of participants, 4 were postmenopausal women, 4 were females, 4 were males, 9 involved both males and females. The detection methods of *H. pylori* were mainly ELISA and ¹³C-urea breath test, while the detection methods of osteoporosis were dual-energy X-ray absorptiometry (DEXA) and quantitative ultrasound. As to the diagnosis, 4 were osteopenia, 14 were osteoporosis, 1 provided both, and 1 provided decreased BMD (treated as osteopenia for analysis) (Table 1). In addition, 13 studies

1
2
3
4 showed no significant associations of *H. pylori* infection and osteoporosis, while 8
5
6 showed significant associations.
7
8

9 **Quality evaluation**

10
11 The Newcastle-Ottawa scale was adopted to evaluate the quality of these case-control
12
13 studies. Among the selection items, the evaluation results ranged from 4 to 8 stars, with
14
15 the median NOS score was 6, indicating a medium quality of the studies included. The
16
17 most common source of bias mainly happened in selection and comparability. (Table 1)
18
19

20 **Synthesis of the results**

21
22 As shown in Fig. 2, the overall OR was obtained based on the 20 studies involving the *H.*
23
24 *pylori* and osteoporosis (including osteopenia) (a total of 8788 patients and healthy
25
26 controls). The pooled OR and its 95% CI were 1.39 (1.13,1.71), indicating *H. pylori*
27
28 infection was significantly associated with increased risk of osteoporosis/osteopenia. A
29
30 cumulative meta-analysis was conducted with publication year in ascending order, and
31
32 the results indicated that the pooled OR (95% CI) started to show statistical significance
33
34 at 1.57 (95% CI: 1.02,2.41) from the ninth analyzed study, with gradually stabilizing
35
36 results afterwards.
37
38
39
40
41
42
43
44

45 **Subgroup analyses**

46
47 Giving that obvious heterogeneity existed, subgroup analyses were performed based on
48
49 the factors of potential heterogeneity. All 20 studies were involved in these subgroup
50
51 analyses. As one study reported both osteoporosis and osteopenia, it was used in two
52
53 groups based on the data. Fig 3 showed that both osteoporosis and osteopenia were
54
55
56
57
58
59
60

1
2
3
4 significantly associated with *H. pylori* infection with OR (95%CI) of 1.59(1.16, 2.20) and
5
6 1.21(1.03, 1.43) respectively. Although the OR was a little higher in osteoporosis group,
7
8 the meta regression analysis showed no significant difference between these two groups
9
10 (beta=0.37, t=1.37, p=0.18). Therefore, we pooled osteoporosis and osteopenia together
11
12 to analyze other confounding factors.
13
14

15
16
17 Results of subgroup analyses by other risk factors were shown in Table 2. We found that
18
19 males had a little higher risk than females, but did not reach the significant level. No
20
21 significant risk was found in females in the subgroup analysis by whether menopause or
22
23 not. In different countries, we found significant associations between *H. pylori* infection
24
25 and osteoporosis in China, Japan, Korea (three East Asian countries). Other factors that
26
27 may affect the results were presented in Table 2.
28
29
30

31 32 **Publication bias and sensitivity analyses**

33
34
35 Begg's test and Egger's test were employed to examine the pooled values from five or
36
37 more studies, and both indicated no publication bias in any of the analyzed data (Fig 4).
38
39 Sensitivity analysis was conducted for the pooled results by removing any single trial and
40
41 by converting the pooled model (fixed effects model). The overall result didn't change
42
43 significantly by removing any single trial or converting the pooled model, which showed
44
45 stable results.
46
47
48
49

50 51 **Alterations of BMD in *H. pylori* infected population**

52
53 Four studies were involved in this meta-analysis^{24 33 34 41}. As each has more than one
54
55 subgroup data from different DEXA detection locations, we carried out the subgroup
56
57
58
59

1
2
3
4 analysis based on detection location. As shown in supplementary fig 1, all three
5
6 subgroups' and overall results had no significant alterations in BMD.
7
8
9

10 11 **Discussion**

12
13
14 Although osteoporosis isn't a deadly disease, osteoporosis causes huge burden to
15
16 individuals and society owing to its high morbidity. Here, we got a comprehensive result
17
18 by meta-analysis, indicating that *H. pylori* infection may be a risk factor for osteoporosis.
19
20 However, the mechanism is still unclear. Several possible mechanisms may explain this
21
22 result. First, *H. pylori* infection may lead to systemic inflammation, and release of
23
24 cytokines, such as tumor necrosis factor-alpha, interleukin-1 and interleukin-6⁴⁴, which
25
26 may cause bone turnover indirectly. Second, many studies have shown that lower vitamin
27
28 B12 can be associated with *H. pylori* infected subjects⁴⁵. As the folate becomes trapped
29
30 as methyltetrahydrofolate and then interrupts for folate-related DNA synthesis, it is an
31
32 important factor for bone remodeling, the low level of vitamin B12 may result in
33
34 decreased BMD and osteoporosis. Third, *H. pylori* infection may decrease the calcium
35
36 absorption by causing the gastric mucosal atrophy and decreasing acid secretion. Thus,
37
38 eradication of *H. pylori* may increase calcium absorption and stop the process of
39
40 osteoporosis through decreasing the levels of inflammatory cytokines and improving
41
42 gastric mucosal atrophy.
43
44
45
46
47
48
49
50
51

52
53 The present meta-analysis of 20 studies indicated that patients with *H. pylori* infection
54
55 were associated with an estimated 1.39 times higher risk of developing osteoporosis as
56
57
58
59
60

1
2
3
4 compared with those without *H. pylori* infection. Compared with the previous
5
6 meta-analysis^{20 21} (one had 5 studies involving 1321 participants, and one had 4 studies
7
8 involving 520 participants), we had 20 studies involving 8788 participants for the
9
10 association between *H. pylori* infection and osteoporosis with a pooled OR of 1.39
11
12 (1.13,1.71). Thus, the power of our result was increased, and the reliability was higher
13
14 too. Other studies of *H. pylori* infection and osteoporosis risk failed to find an association,
15
16 which may due to the sample size. In the quantitative analysis, the alteration of BMD was
17
18 not significant, with an overall SMD (95%CI) of -0.63(-1.52,0.25), which may due to the
19
20 sample size, as the result had a tendency of decrease. Therefore, more studies with large
21
22 sample size are still needed to verify the alterations of BMD in *H. pylori* infection.

23
24
25
26
27
28
29
30 Despite the significant association between *H. pylori* infection and osteoporosis, obvious
31
32 heterogeneity existed. We found that sex of participates may affect the results. Males had
33
34 higher risk to develop osteoporosis than females when infected with *H. pylori*. However,
35
36 only 7 studies (4 were about postmenopausal women and 3 were about
37
38 non-postmenopausal women) were conducted in female, the results may be not that
39
40 reliable due to the small sample size. Another reason may also be possible, that the
41
42 different degree of osteoporosis may affect the diagnosis and some early patients may be
43
44 regarded as healthy controls. Further studies with dose-response relationship of different
45
46 severity of osteoporosis and prevalence may help to confirm this hypothesis. In the
47
48 subgroup analysis by criteria (osteoporosis and osteopenia), the OR in osteoporosis was a
49
50 little higher than that in osteopenia, which may also help to prove our hypothesis. In the
51
52
53
54
55
56
57
58
59
60

1
2
3
4 subgroup analysis based on countries, significant association was evidenced in three
5
6 East-Asian countries (China, Japan, Korea), indicating many other factors that were
7
8 associated with geography may affect the results.
9

10
11 In our research, we also explored the heterogeneity from diagnosis methods factors. We
12
13 found that the detection methods of osteoporosis (DEXA and quantitative ultrasound)
14
15 affected the pooled results, and the detection locations of DEXA also contributed to the
16
17 heterogeneity. The same situation also happened in the detection methods of *H. pylori*.
18
19 We found ELISA and multi-method strategy may provide more homogeneous results. In
20
21 total, as the heterogeneity still existed obviously, further more studies were still needed.
22
23

24
25 We also compared the quantitative alterations of BMD in *H. pylori* infected subjects.
26
27 However, no significant difference was found. The reason may be that: 1) the sample size
28
29 was relatively small, 2) the severities of osteoporosis were not serious, or the infection of
30
31 *H. pylori* didn't last long enough to cause alterations, 3) though the basic characteristics
32
33 of included studies were comparable, many confounding factors that might affect BMD
34
35 have not been adjusted.
36
37

38
39 The strength of the present meta-analysis lies in inclusion of 21 observational studies
40
41 reporting data on *H. pylori* infection and osteoporosis, and the alterations of BMD by *H.*
42
43 *pylori*. However, our meta-analysis has several limitations that should be recognized
44
45 when interpreting the results. First, most of the included studies were hospital-based or
46
47 health center-based, which were not affected by detection bias, but might be subjected to
48
49 selection bias. However, the prevalence of *H. pylori* infection in most studies that we
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 selected was consistent with the incidence rate in the general population. Second, our
5
6 analysis had an ascertainment bias that might be present because progression of
7
8 osteoporosis is continuous, and some patients may be classified as controls. However,
9
10 this may lead to a more conservative result, which may help to indicate that our overall
11
12 result is reliable. Third, the heterogeneity is still obvious. However, we performed
13
14 subgroup analyses based on study characteristics, and found that some factors may affect
15
16 the association and some may not. Four, the qualities of included studies were medium,
17
18 and some studies were published informally. We also included all these studies based on
19
20 inclusion and exclusion criteria to avoid publication bias. However, our study is still the
21
22 most comprehensive result about the association between *H. pylori* positive and
23
24 osteoporosis so far.
25
26
27
28
29
30

31
32 In summary, our results suggest a significant increased risk of osteoporosis in patients
33
34 with *H. pylori* infection. The clinicians should pay more attentions to the patients infected
35
36 with *H. pylori*, especially those chronic gastritis patients. However, the result should be
37
38 cautiously interpreted due to the inclusion of underpowered studies. Further large
39
40 prospective studies are still needed to address the association between *H. pylori* infection
41
42 and osteoporosis and its potential confounding factors.
43
44
45
46
47
48
49
50
51
52
53
54
55

56 Funding

57
58
59
60

1
2
3
4 This work was supported by the National Natural Science Foundation of China [No.
5
6 81202220 to Y. Z.; No. 81673211 and 81372952 to T. C.], by the Natural Science
7
8 Foundation of Jiangsu Province, China [No. BK20150094 to Q.Z.], and by the
9
10 Chongqing Health and Family Planning Commission [No. 20141027 to H. X.].
11
12
13

14 **Contributors**

15
16
17 YZ and HX led the study by designing, interpreting results, and revising manuscript
18
19 critically for important intellectual content; TW and XL contributed to data analysis,
20
21 result interpretation and drafting of the manuscript; QZ and YL participated in study data
22
23 collection and revising manuscript; TW, XL, TC and YZ participated in study conduct
24
25 and results interpretation. All authors read and approved the final manuscript.
26
27
28

29 **Competing interests**

30
31
32 The authors declare that they have no competing interests.
33
34

35 **Patient consent** Not required.
36

37 **Provenance and peer review** Not commissioned; externally peer reviewed.
38
39

40 **Data sharing statement** No additional data are available.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reference

1. Zeng MD, Fan JG, Lu LG, et al. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. *J Dig Dis* 2008;9(2):108-12. doi: 10.1111/j.1751-2980.2008.00331.x [published Online First: 2008/04/19]
2. Lu L-j, Hao N-B, Liu J-J, et al. Correlation between Helicobacter pylori Infection and Metabolic Abnormality in General Population: A Cross-Sectional Study. *Gastroenterology research and practice* 2018
3. Ozaydin N, Turkyilmaz SA, Cali S. Prevalence and risk factors of Helicobacter pylori in Turkey: a nationally-representative, cross-sectional, screening with the (1)(3)C-Urea breath test. *BMC public health* 2013;13:1215. doi: 10.1186/1471-2458-13-1215 [published Online First: 2013/12/24]
4. Dorji D, Dendup T, Malaty HM, et al. Epidemiology of Helicobacter pylori in Bhutan: the role of environment and Geographic location. *Helicobacter* 2014;19(1):69-73. doi: 10.1111/hel.12088 [published Online First: 2013/10/10]
5. Eusebi LH, Zagari RM, Bazzoli F. Epidemiology of Helicobacter pylori infection. *Helicobacter* 2014;19 Suppl 1:1-5. doi: 10.1111/hel.12165 [published Online First: 2014/08/30]
6. den Hollander WJ, Holster IL, den Hoed CM, et al. Ethnicity is a strong predictor for Helicobacter pylori infection in young women in a multi-ethnic European city. *J Gastroenterol Hepatol* 2013;28(11):1705-11. doi: 10.1111/jgh.12315 [published Online First: 2013/07/03]
7. Zhou Y, Ye Z, Huang J, et al. High prevalence and low spontaneous eradication rate of Helicobacter pylori infection among schoolchildren aged 7-12 years. *Acta Paediatr* 2018 doi: 10.1111/apa.14387 [published Online First: 2018/05/04]
8. Pereira MI, Medeiros JA. Role of Helicobacter pylori in gastric mucosa-associated lymphoid tissue lymphomas. *World journal of gastroenterology* 2014;20(3):684-98. doi: 10.3748/wjg.v20.i3.684 [published Online First: 2014/02/28]
9. Bellos I, Daskalakis G, Pergialiotis V. Helicobacter pylori infection increases the risk of developing preeclampsia: A meta-analysis of observational studies. *Int J Clin Pract* 2018;72(2) doi: 10.1111/ijcp.13064 [published Online First: 2018/02/02]
10. Hou Y, Sun W, Zhang C, et al. Meta-analysis of the correlation between Helicobacter pylori infection and autoimmune thyroid diseases. *Oncotarget* 2017;8(70):115691-700. doi: 10.18632/oncotarget.22929 [published Online First: 2018/02/01]
11. Rahmani Y, Mohammadi S, Babanejad M, et al. Association of Helicobacter Pylori with Presence of Myocardial Infarction in Iran: A Systematic Review and Meta-Analysis. *Ethiopian journal of health sciences* 2017;27(4):433-40. [published Online First: 2017/12/09]
12. Wijarnpreecha K, Chesdachai S, Thongprayoon C, et al. Association of Helicobacter pylori with the Risk of Hepatic Encephalopathy. *Digestive diseases and sciences* 2017;62(12):3614-21. doi: 10.1007/s10620-017-4834-1 [published Online First: 2017/11/10]
13. Abdollahi A, Etemadian M, Shoar S, et al. Is Helicobacter pylori Infection a Risk Factor for Prostatitis? A Case-Control Study in a Referring Tertiary Care Center. *Iranian journal of pathology* 2016;11(4):323-27. [published Online First: 2017/09/01]

14. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. *The American journal of medicine* 1993;94(6):646-50. [published Online First: 1993/06/01]
15. Wu TY, Hu HY, Lin SY, et al. Trends in hip fracture rates in Taiwan: a nationwide study from 1996 to 2010. *Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA* 2017;28(2):653-65. doi: 10.1007/s00198-016-3783-4 [published Online First: 2016/11/20]
16. Hernlund E, Svedbom A, Ivergard M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). *Arch Osteoporos* 2013;8:136. doi: 10.1007/s11657-013-0136-1 [published Online First: 2013/10/12]
17. Asaoka D, Nagahara A, Shimada Y, et al. Risk factors for osteoporosis in Japan: Is it associated with *Helicobacter pylori*? *Therapeutics and clinical risk management* 2015;11((Asaoka D., daisuke@juntendo.ac.jp; Nagahara A.; Shimada Y.; Matsumoto K.; Ueyama H.; Matsumoto K.; Nakagawa Y.; Takeda T.; Tanaka I.; Sasaki H.; Osada T.; Hojo M.; Watanabe S.) Department of gastroenterology, University of Juntendo, School of Medicine, Tokyo, Japan):381-91. doi: 10.2147/tcrm.s80647
18. Yoshimura N, Suzuki T, Hosoi T, et al. Epidemiology of hip fracture in Japan: incidence and risk factors. *Journal of bone and mineral metabolism* 2005;23 Suppl:78-80. [published Online First: 2005/06/30]
19. Liu K, Liu P, Liu R, et al. Relationship between serum leptin levels and bone mineral density: a systematic review and meta-analysis. *Clinica chimica acta; international journal of clinical chemistry* 2015;444:260-3. doi: 10.1016/j.cca.2015.02.040 [published Online First: 2015/03/10]
20. Upala S, Sanguankeo A, Wijarnpreecha K, et al. Association between *Helicobacter pylori* infection and osteoporosis: a systematic review and meta-analysis. *Journal of bone and mineral metabolism* 2016;34(4):482-3. doi: 10.1007/s00774-015-0703-1 [published Online First: 2015/08/22]
21. Jaruvongvanich V, Upala S, Wijarnpreecha K, et al. Association between *helicobacter pylori* and osteoporosis: A systematic review and meta-analysis. *American Journal of Gastroenterology* 2015;110((Jaruvongvanich V.) University of Hawaii, Internal Medicine Residency Program, John A. Burns School of Medicine, Honolulu, HI, United States):S1021. doi: 10.1038/ajg.2015.281
22. Chinda D, Shimoyama T, Matsuzaka M, et al. *Helicobacter pylori* infection is not a risk for osteopenia in Japanese healthy males. *American Journal of Gastroenterology* 2016;111((Chinda D.; Shimoyama T.; Fukuda S.) Department of Gastroenterology, Hirosaki University, Graduate School of Medicine, Hirosaki, Aomori, Japan):S1289. doi: 10.1038/ajg.2016.390
23. Chinda D, Shimoyama T, Matsuzaka M, et al. Decrease of estradiol and several life style factors, but not *helicobacter pylori* infection, are significant risks for osteopenia in Japanese females. *American Journal of Gastroenterology* 2016;111((Chinda D.; Shimoyama T.; Fukuda S.) Department of Gastroenterology, Hirosaki University, Graduate School of Medicine, Hirosaki, Aomori, Japan):S499. doi: 10.1038/ajg.2016.363
24. Kalantarhormozi MR, Assadi M, Vahdat K, et al. *Chlamydia pneumoniae* and *Helicobacter pylori* IgG seropositivities are not predictors of osteoporosis-associated bone loss: a prospective cohort

- study. *Journal of bone and mineral metabolism* 2016;34(4):422-28. doi: 10.1007/s00774-015-0688-9
25. Zhang C, Guo L, Hou W, et al. Relationship between the interaction of gastric helicobacter pylori infection and polymorphism of TLR4 gene G11367C and NADPH oxidase gene His72Tyr and the idiopathic osteoporosis in adults. *Chinese Journal of Osteoporosis* 2016;22(5):515-23.
26. Abdolahi N, Aghaei M, Naghdi M. Helicobacter pylori infection and osteoporosis in post menopausal women. *Annals of the Rheumatic Diseases* 2017;76((Abdolahi N.; Aghaei M.; Naghdi M.) Golestan Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran):1354. doi: 10.1136/annrheumdis-2017-eular.6445
27. Chinda D, Shimoyama T, Iino C, et al. Decrease of Estradiol and Several Lifestyle Factors, but Not Helicobacter pylori Infection, Are Significant Risks for Osteopenia in Japanese Females. *Digestion* 2017;96(2):103-09. doi: 10.1159/000479317
28. Pan BL, Huang CF, Chuah SK, et al. Relationship between Helicobacter pylori infection and bone mineral density: a retrospective cross-sectional study. *BMC Gastroenterol* 2018;18(1):54. doi: 10.1186/s12876-018-0780-4 [published Online First: 2018/04/28]
29. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6(7):e1000097. doi: 10.1371/journal.pmed.1000097 [published Online First: 2009/07/22]
30. Ottawa Hospital Research Institute, "The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses," 2011, http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
31. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315(7109):629-34. [published Online First: 1997/10/06]
32. Mizuno S, Matsui D, Watanabe I, et al. Serologically Determined Gastric Mucosal Condition Is a Predictive Factor for Osteoporosis in Japanese Men. *Digestive diseases and sciences* 2015;60(7):2063-69. doi: 10.1007/s10620-015-3576-1
33. Fotouk-Kiai M, Hoseini SR, Meftah N, et al. Relationship between Helicobacter pylori infection (HP) and bone mineral density (BMD) in elderly people. *Caspian journal of internal medicine* 2015;6(2):62-66.
34. Chung YH, Gwak JS, Hong SW, et al. Helicobacter pylori: A Possible Risk Factor for Bone Health. *Korean journal of family medicine* 2015;36(5):239-44. doi: 10.4082/kjfm.2015.36.5.239 [published Online First: 2015/10/06]
35. Asaoka D, Nagahara A, Shimada Y, et al. Risk factors for osteoporosis-are infection or eradication of helicobacter pylori associated? *Gastroenterology* 2015;148(4):S337-S38.
36. Lin SC, Koo M, Tsai KW. Association between helicobacter pylori infection and risk of osteoporosis in elderly Taiwanese women with upper gastrointestinal diseases: A retrospective patient record review. *Gastroenterology research and practice* 2014;2014((Lin S.-C., t780927t@yahoo.com.tw; Tsai K.-W., cktsai@aol.com) Department of Geriatrics, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, 2 Minsheng Road, Dalin, Chiayi 62247, Taiwan) doi: 10.1155/2014/814756
37. Asaoka D, Nagahara A, Shimada Y, et al. H.pylori infection is a risk factor of osteoporosis in Japan. *Gastroenterology* 2014;146(5):S-504. doi: 10.1016/s0016-5085(14)61821-7

- 1
2
3 38. Asaoka D, Nagahara A, Hojo M, et al. The Relationship between H-pylori Infection and Osteoporosis in
4 Japan. *Gastroenterology research and practice* 2014
5
6 39. Chinda D, Shimoyama T, Matsuzaka M, et al. Assessment of the association between helicobacter
7 pylori infection and osteopenia in japanese healthy adults. *Helicobacter* 2013;18((Chinda D.;
8 Shimoyama T.; Matsuzaka M.; Nakaji S.; Fukuda S.) Hirosaki University Graduate, School of
9 Medicine, Hirosaki, Japan):114. doi: 10.1111/hel.12079
10
11 40. Akkaya N, Akkaya S, Polat Y, et al. Helicobacter Pylori Seropositivity in Patients with Postmenopausal
12 Osteoporosis. *Journal of Physical Therapy Science* 2011;23(1):61-64.
13
14 41. Kakehasi AM, Rodrigues CB, Carvalho AV, et al. Chronic gastritis and bone mineral density in women.
15 *Digestive diseases and sciences* 2009;54(4):819-24. doi: 10.1007/s10620-008-0417-5 [published
16 Online First: 2008/08/08]
17
18 42. Kakehasi AM, Mendes CMC, Coelho LGV, et al. The presence of Helicobacter pylori in postmenopausal
19 women is not a factor to the decrease of bone mineral density. *Arquivos de gastroenterologia*
20 2007;44(3):266-70.
21
22 43. Figura N, Gennari L, Merlotti D, et al. Prevalence of Helicobacter pylori infection in male patients with
23 osteoporosis and controls. *Digestive diseases and sciences* 2005;50(5):847-52. doi:
24 10.1007/s10620-005-2651-4
25
26 44. Noach LA, Bosma NB, Jansen J, et al. Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and
27 interleukin-8 production in patients with Helicobacter pylori infection. *Scand J Gastroenterol*
28 1994;29(5):425-9. [published Online First: 1994/05/01]
29
30 45. Kalkan C, Karakaya F, Tuzun A, et al. Factors related to low serum vitamin B12 levels in elderly patients
31 with non-atrophic gastritis in contrast to patients with normal vitamin B12 levels. *Geriatrics &*
32 *gerontology international* 2016;16(6):686-92. doi: 10.1111/ggi.12537 [published Online First:
33 2015/06/06]
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Figure legend
5

6 Fig 1. Flow diagram of the article selection for systematic review.
7

8
9 Fig 2. Meta-analysis of overall OR (random effects models). Left, standard technique;
10
11 Right, cumulative technique.
12

13
14 Fig 3. Subgroup meta-analysis according to diagnosis (random effects models).
15

16
17 Fig 4. Funnel plot (publication bias assessment plot) of the odds ratio.
18

19
20 Supplementary figure 1. Meta-analysis of SMD according to detection locations.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Characteristics and quality assessment of the included studies on Helicobacter pylori infection and risk of osteoporosis.

| Author | Year | Population | Sex(M/F) | Age(mean age±SD or (range age) years) | Detection method of H.pylori | Detection methods of osteoporosis | Diagnosis locations | Diagnosis | Total | Scores of NOS | Adjusted factors |
|---------------------|------|------------|----------------------|--|------------------------------|-----------------------------------|---------------------------|--------------------------|-------|---------------|---|
| Figura, N. | 2005 | Italy | Males | 65 (55–82) for patients; 64.5(55–80) for controls | ELISA | DEXA | Lumbar and femur bone | Osteoporosis | 240 | 7 | Patients and controls were comparable on age, socioeconomic background, and smoking habits. |
| Adriana M. KAKEHASI | 2007 | Brazil | Postmenopausal women | 61.6±7(50–79) | non-ELISA | DEXA | Lumbar spine | Osteoporosis | 50 | 6 | mean age, body mass index, age at menarche, or postmenopausal period |
| Adriana M. Kakehasi | 2009 | Italy | Females | Not mentioned | non-ELISA | DEXA | Lumbar spine and hip | Not fitted* | 61 | - | Age, Postmenopausal time, BMI |
| Akkaya, Nuray | 2011 | Turkey | Postmenopausal women | 65.29±6.09 patients; 63.57±6.53 controls | ELISA | DEXA | Lumbar and femur neck | Osteoporosis | 105 | 6 | Age, education level, occupation, age of menarche or menopause, duration of postmenopausal, period or daily consumption of tea, coffee, alcohol or dairy products |
| Chinda, D. | 2013 | Japan | 379/631 | not mentioned | ELISA | QU | Calcaneal osteo | Osteopenia | 1010 | 7 | multivariate Logistic Regression analysis |
| Asaoka, Daisuke | 2014 | Japan | 95/105 | 63.1±8.8 years | Both | DEXA | Lumbar vertebrae | Osteoporosis | 200 | 6 | Multivariate Logistic Regression Analysis: age, gender, BMI, alcohol consumption, smoking, H. pylori infection, BAP, PUD, and EGA |
| Asaoka, D. | 2014 | Japan | 131/26 | 71.1±7.5 patients 61.6±8.9 controls | not mentioned | DEXA | Lumbar | Osteoporosis | 157 | 6 | multivariate Logistic Regression analysis (age, sex, BMI, etc.) |
| Lin, S. C. | 2014 | China | Female | 77 (65–97) | non-ELISA | DEXA | Not mentioned | Osteoporosis | 365 | 5 | multivariate logistic regression analyses (age group, body mass index group, and use of proton pump inhibitor, etc.) |
| Asaoka, D. | 2015 | Japan | 130/134 | 69.8±6.8 for patients 1.9±8.2 for controls | not mentioned | DEXA | Not mentioned | Osteoporosis | 264 | 7 | multivariate analysis (age, sex, BMI etc.) |
| Asaoka, D. | 2015 | Japan | 120/135 | 63.2±8.5 | Both | DEXA | Lumbar vertebrae | Osteoporosis | 255 | 6 | Multivariate analysis (age, sex, BMI, BAP, Comorbidities etc.) |
| Chung, Y. H. | 2015 | Korea | Men | 54.4± 10.7 for Hp+ 51.9± 12.1 for Hp- | ELISA | DEXA | Lumbar (L1–L4) | Osteoporosis, osteopenia | 1126 | 7 | unadjusted |
| Fotouk-Kiai, M. | 2015 | Iran | 575/392 | 68.3±6.8 for hp+ 69.3±7.4 for hp- | ELISA | DEXA | Lumbar vertebra and Femur | Osteoporosis | 967 | 5 | Age, sex, smoking, alcohol consumption and BMI |
| Mizuno, S. | 2015 | Japanese | Men | 62.1±5.0 for low TBD; 58.4±5.7 for normal | ELISA | QU | Not mentioned | Osteoporosis | 230 | 8 | Age- and BMI-adjusted |
| Chinda, D. | 2016 | Japan | Men | 50.2±15.4 years | ELISA | QU | Not mentioned | Osteopenia | 295 | 7 | multivariate logistic regression analyses: age, BMI, serum level of estradiol, the intake of calcium per day, smoking, drinking, periodical exercise, last educational background |

| | | | | | | | | | | | | |
|----|-------------------------|------|-------|----------------------|---|-----------|---------------|---------------|---------------|------|---|--|
| 1 | Chinda, D. | 2016 | Japan | Females | 52.2±15.2 | ELISA | QU | Not mentioned | Osteopenia | 473 | 6 | multiple logistic regression models: age, BMI, smoking, alcohol consumption, periodical exercise, last educational level, serum level of estradiol, calcium intake per day |
| 2 | | | | | | | | | | | | |
| 3 | | | | | | | | | | | | |
| 4 | Kalantarhor mozi, M. R. | 2016 | Iran | Postmenopausal women | 58.87±8.02 | ELISA | DEXA | Not mentioned | Osteoporosis | 250 | 6 | not mentioned |
| 5 | | | | | | | | | | | | |
| 6 | | | | | | | | | | | | |
| 7 | Zhang, Chaoxian | 2016 | China | 194/126 | 38.32±10.64 for patients: 38.27±7.46 for controls | non-ELISA | DEXA | Not mentioned | Osteoporosis | 320 | 5 | Multiple logistic regression models some basic characters and genes |
| 8 | | | | | | | | | | | | |
| 9 | | | | | | | | | | | | |
| 10 | Abdolahi, N. | 2017 | Iran | Postmenopausal women | not mentioned | ELISA | not mentioned | Not mentioned | Osteoporosis | 107 | 8 | not mentioned |
| 11 | | | | | | | | | | | | |
| 12 | | | | | | | | | | | | |
| 13 | Chinda, D. | 2017 | Japan | Females | 62.5±8.6 for patients 44.9±10.9 for controls | ELISA | QU | Calcaneus | Osteopenia | 473 | 4 | Multiple logistic regression analysis: Age, BMI, Smoking, Alcohol, Exercise habit, Schooling duration, Estradiol levels, Birth history Calcium intake |
| 14 | | | | | | | | | | | | |
| 15 | | | | | | | | | | | | |
| 16 | Lu, Li-juan | 2018 | China | 1474/393 | 54.0±9.6 | non-ELISA | QU | Calcaneus | Osteoporosis | 1867 | 6 | not mentioned |
| 17 | | | | | | | | | | | | |
| 18 | | | | | | | | | | | | |
| 19 | Pan, B. L. | 2018 | China | 568/299 | 55.9±11.3 | non-ELISA | DEXA | Not mentioned | Decreased BMD | 867 | 5 | Multiple stepwise logistic regression analysis: Sex, BMI, Waist circumference, Total cholesterol, HDL, TG, LDL, Peptic ulcer, GERD |
| 20 | | | | | | | | | | | | |
| 21 | | | | | | | | | | | | |

Not fitted *: this study only explored the alteration of BMD in patients with *H. pylori* infection.

ELISA: enzyme linked immunosorbent assay; QU: quantitative ultrasound; DEXA: dual energy X-ray absorptiometry scan;

Table 2. Overall effect estimates for *Helicobacter pylori* infection and osteoporosis risk according to study characteristics

| Factors | Categories | No. of studies | OR [95%CI] | Heterogeneity | |
|---------------------------------------|--------------------------|----------------|------------------|----------------|----------|
| | | | | I ² | p-value |
| Sex | | | | 34.9% | P > 0.05 |
| | Male | 5 | 1.37(1.15,1.62) | 24.6% | P > 0.05 |
| | Female | 8 | 1.09(0.87,1.34) | 33.0% | P > 0.05 |
| Postmenopausal or not | | | | | |
| | Postmenopausal women | 4 | 1.05(0.64,1.72) | 35.8% | P > 0.05 |
| | Non-postmenopausal women | 3 | 1.21(0.74,1.97) | 57.3% | P > 0.05 |
| Country | | | | | |
| | China | 4 | 1.90(1.11,3.24) | 89.0% | P < 0.05 |
| | Japan | 9 | 1.57(1.08,2.28) | 63.7% | P < 0.05 |
| | Italy | 1 | 0.87(0.50,1.53) | - | - |
| | Brazil | 1 | 0.42(0.12,1.42) | - | - |
| | Korea | 1 | 1.43(1.17,1.74) | - | - |
| | Iran | 3 | 1.06(0.60,1.86) | 61.3% | P > 0.05 |
| | Turkey | 1 | 0.95(0.53,1.69) | - | - |
| Detection methods of <i>H. pylori</i> | | | | | |
| | ELISA | 11 | 1.08(0.89,1.32) | 46.3% | P < 0.05 |
| | Non-ELISA | 5 | 1.62(0.96,2.72) | 87.0% | P < 0.05 |
| | Both | 2 | 3.67(1.88, 7.16) | 0% | P > 0.05 |
| Antibody of ELISA | | | | | |
| | IgA | 2 | 1.40(0.78,2.48) | 9.8% | P > 0.05 |
| | IgG | 2 | 1.07(0.55,2.07) | 0% | P > 0.05 |
| Detection methods of osteoporosis | | | | | |
| | DEXA | 13 | 1.60(1.16,2.21) | 79.6% | P < 0.05 |
| | QU | 6 | 1.11(0.95,1.29) | 0% | P > 0.05 |
| Detection location of DEXA | | | | | |
| | Lumbar | 6 | 1.50(1.18,1.91) | 65.4% | P < 0.05 |
| | Femur | 3 | 1.56(1.17,2.08) | 0% | P > 0.05 |

ELISA: enzyme linked immunosorbent assay; QU: quantitative ultrasound; DEXA: dual energy

X-ray absorptiometry scan.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Fig 1

199x194mm (300 x 300 DPI)




Fig 2

549x230mm (300 x 300 DPI)




Fig 3

283x252mm (300 x 300 DPI)





Fig 4

139x101mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



533x371mm (72 x 72 DPI)

PRISMA Checklist

| Section/topic | # | Checklist item | Reported on page # |
|------------------------------------|----|---|--------------------|
| TITLE | | | |
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both. | 1 |
| ABSTRACT | | | |
| Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 2 |
| INTRODUCTION | | | |
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. | 3 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 4 |
| METHODS | | | |
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | NA |
| Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 5 |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 5 |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | 5 |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 5 |
| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 6 |
| Data items | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | 6 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | 6 |
| Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means). | 7 |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I ²) for each meta-analysis. | 7 |

PRISMA Checklist

| Section/topic | # | Checklist item | Reported on page # |
|-------------------------------|----|--|--------------------|
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | 7 |
| Additional analyses | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | 7 |
| RESULTS | | | |
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | 8 |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | 8 |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | 10 |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. | NA |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | 9 |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15). | 9 |
| Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). | 8 |
| DISCUSSION | | | |
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). | 11 |
| Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | 13 |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research. | 14 |
| FUNDING | | | |
| Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | 14 |

BMJ Open

Relationship between *Helicobacter pylori* infection and osteoporosis: A systematic review and meta-analysis

| | |
|---------------------------------|--|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2018-027356.R1 |
| Article Type: | Research |
| Date Submitted by the Author: | 04-Mar-2019 |
| Complete List of Authors: | Wang, Taiwu; Third Military Medical University, Department of Epidemiology Li, Xiang; The Southwest Medical University, School of pharmacy Zhang, Qi; Center for Disease Control and Prevention of Eastern Theater Command Ge, Bingjie; 95810 Unit, The Chinese People's Liberation Army Zhang, Jinhai; Center for Disease Control and Prevention of Eastern Theater Command Yu, Lei; Third Military Medical University, Department of Epidemiology Cai, Tongjian; Third Military Medical University, Department of Epidemiology Zhang, Yao Xiong, Hongyan |
| Primary Subject Heading: | Epidemiology |
| Secondary Subject Heading: | Infectious diseases, Epidemiology |
| Keywords: | osteoporosis, bone mineral density, <i>Helicobacter pylori</i> , meta-analysis |
| | |

SCHOLARONE™
Manuscripts

Original article

Relationship between *Helicobacter pylori* infection and osteoporosis:

A systematic review and meta-analysis

Running Title: Relationship between *H. pylori* and osteoporosis

Taiwu Wang^{1,2,*}, Xiang Li^{3,*}, Qi Zhang², Bingjie Ge⁴, Jinhai Zhang², Lei Yu¹, Tongjian Cai¹,
Yao Zhang^{1,†}, Hongyan Xiong^{1,†}

¹ Department of Epidemiology, College of Preventive Medicine, Third Military Medical University, Chongqing 400038, People's Republic of China.

² Center for Disease Control and Prevention of Eastern Theater Command, Nanjing 210002, People's Republic of China.

³ School of pharmacy, The Southwest Medical University, Luzhou 646000, People's Republic of China.

⁴ 95810 Unit, The Chinese People's Liberation Army, Beijing 100076, People's Republic of China.

* These authors contributed equally to this work.

† These authors jointly supervised this work.

Corresponding author's information: Hongyan Xiong,

Address: Gaotanyan Road 30, Shapingba District, Chongqing 400038, China,

E-mail: hongyanxiong@126.com, Tel: +86-023-687752295.

Word count: 3311

Abstract

Objectives Many studies have explored the association between *Helicobacter pylori* (*H. pylori*) infection and osteoporosis. However, the results remain controversial. Therefore, we performed this systematic review and meta-analysis to evaluate the association between *H. pylori* infection and osteoporosis.

Design Systematic review and meta-analysis of case-control studies.

Data sources Databases, including PubMed, Embase, Web of Science and CBM, were screened from inception to April 30, 2018.

Eligibility Criteria Case-control studies aimed at assessing the association between *H. pylori* infection and osteoporosis.

Data extraction and analysis Study characteristics and study quality sections were reviewed. Studies were selected, and data were extracted by two reviewers. Pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated using random effects model if heterogeneity existed, otherwise fixed effects model was used. Subgroup analyses were performed to explore the source of heterogeneity. Publication bias and sensitivity analyses were also tested.

Results A total of 21 studies with 9655 participants were included in our analyses. Taking together, we found that *H. pylori* infection was significantly associated with increased odds of osteoporosis (OR (95%CI): 1.39(1.13–1.71)); there was no significant difference between osteoporosis and osteopenia; the association between osteoporosis and *H. pylori* infection was relatively higher in males than females, but didn't reach significant level. However, the decrease of bone mineral density in *H.*

1
2
3
4 *pylori* positive patients was not significant when compared with *H. pylori* negative
5
6 controls, which may due to the sample size.
7

8
9 **Conclusions** Our meta-analysis suggested that *H. pylori* infection was significantly
10 associated with increased odds of osteoporosis. The clinicians should pay more
11 attention to the patients infected with *H. pylori*. Further studies were still needed to
12 exploring the confounding factors among studies and to elucidate the underlying
13 biological mechanisms.
14
15
16
17
18
19
20
21

22 **Keywords:** osteoporosis; bone mineral density; *Helicobacter pylori*; meta-analysis.
23
24
25
26
27
28
29
30
31

32 **Strengths and limitations of this study**

- 33
34
35 ▶ 21 studies with conflicting results were included for testing the association between
36 osteoporosis and *Helicobacter pylori* infection.
37
38 ▶ This is the third and most comprehensive meta-analysis, bringing the overall results
39 of statistical significance and increased odds.
40
41 ▶ From our results, the clinicians should pay more attention to the male patients
42 infected with *H. pylori*.
43
44 ▶ The results of the meta-analysis should be interpreted with caution due to the
45 number and quality of studies included, and obvious heterogeneity.
46
47 ▶ Causality can't be established in observational study.
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Helicobacter pylori (*H. pylori*), a Gram-negative and spiral-shaped bacterium dwelling on the gastric epithelium, has an influence on approximately 50% of the global population, especially those living in developing countries¹. The prevalence of *H. pylori* infection is approximately 30% in developed countries and up to 80% in developing countries^{2,3}, and up to 90% in patients with dyspepsia⁴. In North Europe and North America, about one-third of adults are infected, and in South and East Europe, South America, and Asia, the prevalence of *H. pylori* is often higher than 50%⁵. Moreover, infected subjects born abroad (first-generation immigrants) had a higher risk of *H. pylori* infection than second-generation immigrants in a multi-ethnic European city⁶. *H. pylori* has been well-known to be associated with gastrointestinal diseases, such as gastritis, gastric ulcer, stomach cancer and so on⁷. Furthermore, some non-gastrointestinal diseases have also been proven to be associated with *H. pylori* by large-scale population researches or meta-analysis, such as preeclampsia⁸, autoimmune thyroid diseases⁹, myocardial infarction¹⁰, hepatic encephalopathy¹¹ and prostatitis¹².

Osteoporosis is one of the most common metabolic bone diseases, characterized by decreased bone mineral density (BMD), increased bone fragility, and then increased susceptibility to fracture¹³, especially in spine and hip. Osteoporosis has become a major health concern for both individuals and societies. Osteoporosis has huge adverse impacts on life quality and is associated with increased morbidity rates. The in-hospital mortality rate is between 0.85 to 2.26%¹⁴. In Europe, about half of women

1
2
3
4 and one-fifth of men aged over fifty years develop pathological fractures in hip, spine,
5
6 forearm, or humerus due to osteoporosis during their remaining lifetime¹⁵. The same
7
8 situation happens in other countries or districts, such as Japan and Taiwan^{16 17}.

9
10
11 There are well established evidence regarding the risk factors for osteoporosis ¹⁷, such
12
13 as age, sex, body mass index (BMI), alcohol, and smoking. *H. pylori* infection can
14
15 induce inflammatory and immune responses, such as increasing the level of IL-1 and
16
17 TNF- α , which could trigger bone resorption, and regulate bone regeneration¹⁸.
18
19 Recently, many studies about the association between osteoporosis and *H. pylori* have
20
21 been performed. However, the role of *H. pylori* in osteoporosis remains controversial.
22
23 This issue has been discussed in previous meta-analysis ^{19 20}, but no significant
24
25 association was found. As more studies evaluating the association between *H. pylori*
26
27 infection and osteoporosis have been published since then ^{2 21-27}, we carried out this
28
29 updated meta-analysis to further evaluate the association between *H. pylori* infection
30
31 and osteoporosis qualitatively, and the quantitative alterations of BMD in *H. pylori*
32
33 infected patients compared with those in healthy controls.
34
35
36
37
38
39
40
41
42
43
44
45

46 **Materials and Methods**

47
48 This study was performed based on preferred reporting items for systematic reviews
49
50 and meta-analyses (PRISMA)²⁸. Study searching and selection, quality assessment,
51
52 and data extraction were done by two researchers (TW and XL) independently to
53
54 avoid bias, and disagreements were discussed by the two reviewers and by seeking the
55
56 opinion of the third author (YZ) if necessary.
57
58
59
60

Search strategy

We searched through the databases of PubMed, Embase, Web of Science and Chinese Biomedical Literature Database (CBM). The last search for all databases was updated to April 30, 2018. We used the combined method of MeSH Term and free words by applying the following terms: *Helicobacter pylori*, *campylobacter pylori*, *H. pylori*, *hp*, *helicobacter*, *helicobacter bill*, *helicobacter hepaticus*, *helicobacter pullorum*, *helicobacter species*, *helicobacter sp*, *helicobacter genus*, *campylobacter*, *campylobacter infection*, *campylobacteriosis*, *Helicobacter pylori infection*, *Helicobacter infection*, *pylori*, *enterohepatic helicobacter spp*, *campylobacter sp* and fragility fracture, bone density, bone mass density, osteocalcin, bone loss, osteoporosis. Two authors evaluated potential publications by checking their titles and abstracts and then procured the most relevant publications for further examination. Bibliographies section of retrieved articles were also reviewed for additional pertinent studies which were possibly missed in the initial search.

Studies selection and data extraction

Studies were included if they met the following criteria: (1) it is an observational study; (2) its objective is to assess the association between *H. pylori* infection and osteoporosis, or compare the alteration of BMD between *H. pylori* positive and negative participants; (3) they either provided odds ratios (ORs) and 95% confidence intervals (95% CIs), or sufficient information was available to calculate the ORs and 95% CIs, or BMD in both *H. pylori* positive and negative participants. Articles were excluded if they were duplicate publications, reviews, animal studies, editorials, or

1
2
3
4 case reports. The papers were also excluded if no effect estimate was reported or not
5
6 enough raw data for ORs and 95% CIs calculation was available. In the case of
7
8 multiple studies with the same or overlapping data published by the same researchers,
9
10 we selected the most recent study with the largest number of participants. All papers
11
12 meeting the criteria defined above were included for further analysis.
13
14

15
16
17 The literatures included were carefully reviewed for information about the first author,
18
19 publication year, country, population, sample size, sex, age, detection methods of *H.*
20
21 *pylori* and osteoporosis, diagnosis location, diagnosis, and adjusted covariates.
22
23

24
25 If data could be acquired from the tabulated literature search results, they would be
26
27 extracted carefully into 2x2 tables from all eligible publications by two independent
28
29 reviewers. If data were not directly available, they would be calculated from
30
31 published positive predictive values and/or negative predictive values if appropriate.
32
33

34
35 The adjusted OR (95%CI), if existed, was adopted instead of crude OR (95%CI)²⁹. In
36
37 addition, for the studies comparing the BMD of participants with and without *H.*
38
39 *pylori* infection, the data on BMD was also extracted.
40
41

42 43 **Quality assessment**

44
45 Quality assessment was performed using the Newcastle-Ottawa quality assessment
46
47 scale (NOS)³⁰. Two researchers conducted blinded quality assessment of the included
48
49 literatures. The NOS assigns a maximum of 9 points to studies of highest quality
50
51 according to three quality parameters: selection, comparability, and outcome.
52
53

54 55 **Statistical analyses**

56
57
58 The primary measures were ORs and 95% CIs for the association between *H. pylori*
59
60

1
2
3
4 infection and osteoporosis, and standardized mean difference (SMD) for BMD
5
6 alterations between *H. pylori* positive and negative participants. To assess
7
8 heterogeneity among the studies, we calculated the Cochran's Chi-squared test (with
9
10 $P < 0.10$ indicating statistically significant heterogeneity) and the statistic I^2 (The
11
12 heterogeneity might not be important with I^2 of 0 to 40%, while moderate
13
14 heterogeneity with I^2 of 30 to 60%, substantial heterogeneity with I^2 of 50 to 90% and
15
16 considerable heterogeneity with I^2 of 75 to 100%)³¹. The pooled results were
17
18 calculated using fixed effects model (Inverse Variance) if no obvious heterogeneity
19
20 existed, otherwise random effects model (I-V heterogeneity) was used ($P < 0.10$ was
21
22 considered indicative of obvious heterogeneity). The cumulative meta-analysis was
23
24 conducted for the extracted data using a pooled random effects model with the
25
26 publication year. In the event of obvious heterogeneity, subgroup analysis was
27
28 performed according to sex, postmenopausal or not, country, Asian or not, detection
29
30 methods of *H. pylori*, detection methods of osteoporosis, and detection location of
31
32 dual-energy X-ray absorptiometry (DEXA). Meta regression (using ReML methods)
33
34 was also performed to explore the potential heterogeneity. Publication bias was
35
36 assessed by funnel plot and Egger's test³². A sensitivity analysis was completed by
37
38 converting the pooled results from random effects model into fixed effects model or
39
40 from fixed effects model into random effects model. All statistical analyses were
41
42 performed using Stata 12.0.
43
44
45
46
47
48
49
50
51
52
53
54

55 **Patient and public involvement**

56
57
58 There was no patient and public involvement as this was a database research study.
59
60

Results

Search results

Using our search strategy, a total of 1720 articles were identified through PubMed, Web of Science, Embase and CBM, and one additional record was identified through other sources. Then, 443 duplicate papers were removed firstly, and 1242 papers were excluded after scanning their titles and abstracts. After screening the full texts of the included articles, 15 studies were excluded for the following reasons: duplicate publication(n=4), not about the topic(n=2), no related data about *H. pylori* and/or osteoporosis(n=4), lack of access to full text (n=5). A total of 21 studies^{2 16 21-27 33-44} were included for further analysis (Figure 1).

Study Characteristics

A total of 21 articles were included in this study. Of the 21 articles included, 20 provided data for association between *H. pylori* and osteoporosis^{2 16 21-27 33-41 43 44}, 4 for the BMD alterations in *H. pylori* positive participants compared with negative controls^{23 34 35 42}, 3 provided both^{23 34 35}. All these studies were published from 2005 to 2018. Four studies were conducted in China, 3 in Iran, 1 in Italy, 9 in Japan, 2 in Brazil, 1 in Korea and 1 in Turkey. As to the sex of participants, 4 were postmenopausal women, 4 were females, 4 were males, 9 involved both males and females. The detection methods of *H. pylori* were mainly ELISA and ¹³C-urea breath test, while the detection methods of osteoporosis were DEXA and quantitative ultrasound. As to the diagnosis, 5 were osteopenia, 13 were osteoporosis, and 2 provided decreased BMD (treated as osteopenia for analysis) (Table 1). In addition,

1
2
3
4 12 studies showed no significant associations of *H. pylori* infection and osteoporosis
5
6 (or osteopenia), while 8 showed significant associations.
7
8

9 **Quality evaluation**

10
11 The Newcastle-Ottawa scale (NOS) was adopted to evaluate the quality of these
12 case-control studies. Among the selection items, the evaluation results ranged from 4
13
14 to 8, with the median NOS score was 6, indicating a medium quality of the studies
15
16 included. The most common source of bias came from selection and comparability.
17
18 (Table 1)
19
20
21
22
23

24 **Synthesis of the results**

25
26 As shown in Figure 2, the overall OR was obtained based on the 20 studies involving
27 the *H. pylori* and osteoporosis (including osteopenia) (a total of 8788 patients and
28 healthy controls). As the existence of obvious heterogeneity (Chi-square = 69.60, $I^2 =$
29 72.7%, $P < 0.01$), random effect model was used and the pooled results of OR and its
30 95%CI were 1.37(1.11,1.69), indicating *H. pylori* infection was significantly
31 associated with increased odds of osteoporosis/osteopenia. A cumulative
32 meta-analysis was conducted with publication year in ascending order, and the results
33 indicated that the pooled OR (95% CI) started to show statistical significance at 1.57
34 (95% CI: 1.02,2.41) from the ninth analyzed study, with gradually stabilizing results
35 afterwards (Figure 3).
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 **Subgroup analyses**

53
54 Given that obvious heterogeneity existed, subgroup analyses were performed based
55 on the potential confounding factors. All 20 studies were involved in these subgroup
56
57
58
59
60

1
2
3
4 analyses. Figure 4 showed that both osteoporosis and osteopenia were significantly
5
6 associated with *H. pylori* infection with OR(95%CI) of 1.61(1.11, 2.32) and 1.22(1.07,
7
8 1.39) respectively. Although the OR was a little higher in osteoporosis group, the
9
10 meta regression analysis showed no significant difference between these two groups
11
12 ($t=1.18$, $P=0.26$). Therefore, we pooled osteoporosis and osteopenia together to
13
14 analyze other confounding factors.
15
16
17

18
19 Results of subgroup analyses by other factors were shown in Table 2. We found that
20
21 the association between *H. pylori* infection and osteoporosis was significant in males
22
23 but not in females. However, meta regression analysis showed no significant
24
25 difference between these two groups. Moreover, no significant associations between
26
27 *H. pylori* infection and osteoporosis were observed in either the postmenopausal
28
29 women or non-postmenopausal women subgroup. When stratified by countries, we
30
31 found significant associations between *H. pylori* infection and osteoporosis in China,
32
33 Japan, and Korea (three East Asian countries). Other factors that may affect the
34
35 results were presented in Table 2.
36
37
38
39
40
41
42

43 **Publication bias and sensitivity analyses**

44
45 Funnel plot was used to examine the results of this meta-analysis. As shown in Figure
46
47 5, the funnel plot indicated no publication bias, which was also confirmed by Egger's
48
49 test ($t = 1.57$, $P = 0.13$) (Figure 6). Sensitivity analysis was also performed by
50
51 converting the pooled model from the random effects model to the fixed effects model.
52
53 The result of fixed effects model was 1.21(1.10-1.33), showed no obvious differences
54
55 compared with the result of random effects model, indicating the pooled results was
56
57
58
59
60

1
2
3
4 relatively stable.
5

6 **Alterations of BMD in *H. pylori* infected population**

7
8
9 Four studies were involved in this meta-analysis^{23 34 35 42}. As each study has two
10
11 different detection locations, we performed subgroup analysis based on detection
12
13 locations. As shown in supplementary Figure 1, the BMD(g/cm²) alterations between
14
15 *H. pylori* positive and negative participants were -0.01(-0.45,0.42) for hip,
16
17 -0.94(-3.15,1.28) for lumber and -0.04(-0.40,0.31) for femur using random effects
18
19 model as obvious heterogeneity existed. No significant associations were observed so
20
21 far.
22
23
24
25
26
27
28
29

30 **Discussion**

31
32 Although osteoporosis isn't a deadly disease, it causes huge burden to individuals and
33
34 society owing to its high morbidity. Here, we got a comprehensive result by
35
36 meta-analysis, indicating that *H. pylori* infection may be a risk factor for osteoporosis.
37
38 However, the mechanism is still unclear. Several possible mechanisms may explain
39
40 this result. First, *H. pylori* infection may lead to systemic inflammation, and release of
41
42 cytokines, such as tumor necrosis factor-alpha, interleukin-1 and interleukin-6⁴⁵,
43
44 which may cause bone turnover indirectly. Second, many studies have shown that low
45
46 vitamin B12 may be associated with *H. pylori* infection⁴⁶. If the serum vitamin B12
47
48 levels are decreased, the folate becomes trapped as methyltetrahydrofolate and
49
50 interrupts for folate-related DNA synthesis, which is an important factor for bone
51
52 remodeling. Therefore, the decrease of vitamin B12 may lead to decreased BMD and
53
54
55
56
57
58
59
60

1
2
3
4 osteoporosis⁴⁷. Third, *H. pylori* infection may decrease the calcium absorption by
5
6 causing the gastric mucosal atrophy and decreasing acid secretion. Thus, eradication
7
8 of *H. pylori* may increase calcium absorption and stop the process of osteoporosis
9
10 through decreasing the levels of inflammatory cytokines and improving gastric
11
12 mucosal atrophy.
13
14

15
16
17 The present meta-analysis of 20 studies indicated that patients with *H. pylori* infection
18
19 were associated with an estimated 1.37 times higher odds ratios of developing
20
21 osteoporosis as compared with those without *H. pylori* infection, while no
22
23 associations were found in previous meta-analysis^{19 20} (one had 5 studies involving
24
25 1321 participants, and one had 4 studies involving 520 participants). As the previous
26
27 meta-analysis studies had no quality assessment and our analysis included more
28
29 studies and participants, the results in our study might be more reliable than the
30
31 previous meta-analysis studies.
32
33
34
35
36

37
38 Despite the significant association between *H. pylori* infection and osteoporosis,
39
40 obvious heterogeneity existed between the included studies. We found that sex of
41
42 participants may affect the results. As known to all, female and postmenopausal women
43
44 are independent risk factors of osteoporosis. Here, we explored the relationship
45
46 between osteoporosis and *H. pylori* infection, and found that the relationship was
47
48 significant in male, but not in female (whether postmenopausal or not), which wasn't
49
50 paradoxical with the fact that women with postmenopausal should have a higher risk
51
52 of osteoporosis than men. In the group of both sexes, the results showed statistic
53
54 difference and obvious heterogeneity, which may be due to the ratio of M/F and other
55
56
57
58
59
60

1
2
3
4 confounding factors. Therefore, we might suggest that more attention should be paid
5
6 to male than female in *H. pylori* positive patients. However, only 7 studies (4 were
7
8 about postmenopausal women and 3 were about non-postmenopausal women) were
9
10 conducted in female, the results may be not that reliable due to the small sample size.
11
12 Another reason may also be possible, that the different degree of osteoporosis may
13
14 affect the diagnosis and some early patients may be regarded as healthy controls.
15
16 Further studies with dose-response relationship of different severity of osteoporosis
17
18 and prevalence may help to confirm this hypothesis. In the subgroup analysis by
19
20 criteria (osteoporosis and osteopenia), the OR in osteoporosis was a little higher than
21
22 that in osteopenia, which may also help to prove our hypothesis. In the subgroup
23
24 analysis based on countries, significant association was evidenced in three East-Asian
25
26 countries (China, Japan, Korea), indicating many other factors that were associated
27
28 with geography may affect the results.
29
30
31
32
33
34
35
36

37 In our research, we also explored the heterogeneity from diagnosis methods factors.
38
39 We found that the detection methods of osteoporosis (DEXA and quantitative
40
41 ultrasound) affected the pooled results, and the detection locations of DEXA also
42
43 contributed to the heterogeneity. From our results, we thought that DEXA might be a
44
45 better tool to diagnose osteoporosis in assessing the association between *H. pylori* and
46
47 osteoporosis. The same situation also happened in the detection methods of *H. pylori*.
48
49 We found ELISA and multi-method strategy may provide more homogeneous results.
50
51
52
53
54
55 In total, in despite of the significant association between *H. pylori* and osteoporosis,
56
57 as the heterogeneity still existed obviously, further studies were still needed to address
58
59
60

1
2
3
4 its potential confounding factors.
5

6 In a previous meta-analysis study, Karn Wijarnpreecha et al found increased odds of
7 nonalcoholic fatty liver disease (NAFLD) among patients infected with *H. pylori* ⁴⁸.
8
9 However, Sikarin Upala et al found that no significant difference in BMD between
10 patients with fatty liver disease and controls⁴⁹. Combine the two meta-analysis and
11
12 our results, we may guess that *H. pylori* may be an independent risk factor of NAFLD
13 and osteoporosis, and/or *H. pylori* infection may be an important confounding factor
14 in exploring the relationship between NAFLD and osteoporosis, or no actual
15 relationship between NAFLD and osteoporosis exists. However, as the authors
16 stated⁴⁹, the review was a preliminary result because of limited amount of literature, it
17 might be too early to have definite conclusion.
18
19
20
21
22
23
24
25
26
27
28
29
30
31

32 We also compared the quantitative alterations of BMD in *H. pylori* infected subjects.
33
34 However, no significant difference was found. The reason may be that: 1) the sample
35 size was relatively small, 2) the severities of osteoporosis were not serious, or the
36 infection of *H. pylori* didn't last long enough to cause alterations, 3) though the basic
37 characteristics of included studies were comparable, many other confounding factors
38 that might affect BMD have not been adjusted. Therefore, more studies with large
39 sample size were still needed to verify the alterations of BMD in *H. pylori* infection.
40
41
42
43
44
45
46
47
48
49

50 The strength of the present meta-analysis lies in inclusion of 21 observational studies
51 reporting data on *H. pylori* infection and osteoporosis, and the alterations of BMD by
52
53 *H. pylori*. However, our meta-analysis has several limitations that should be
54
55 recognized when interpreting the results. First, most of the included studies were
56
57
58
59
60

1
2
3
4 hospital-based or health center-based, which were not affected by detection bias, but
5
6 might be subjected to selection bias. However, the prevalence of *H. pylori* infection in
7
8 most studies that we selected was consistent with the incidence rate in the general
9
10 population. Second, our analysis had an ascertainment bias that might be present
11
12 because progression of osteoporosis is continuous, and some patients may be
13
14 classified as controls. However, this may lead to a more conservative result, which
15
16 may help to indicate that our overall result is reliable. Third, the heterogeneity is still
17
18 obvious. However, we performed subgroup analyses based on study characteristics,
19
20 and found that some factors may affect the association. In addition, when available,
21
22 adjusted estimates were used in preference to unadjusted estimates. Even though the
23
24 adjusted estimates may be closer to the true effect, the different adjusted factors in
25
26 different studies may also contribute to the heterogeneity. Four, the qualities of
27
28 included studies were medium, and some studies were published informally. We also
29
30 included all these studies based on inclusion and exclusion criteria to avoid
31
32 publication bias. Nevertheless, our study is still the most comprehensive about the
33
34 association between *H. pylori* infection and osteoporosis.
35
36
37
38
39
40
41
42
43
44

45 In summary, our results suggest significant increased odds of osteoporosis in patients
46
47 with *H. pylori* infection. The clinicians should pay more attentions to the patients
48
49 infected with *H. pylori* by using DEXA scan, especially those chronic gastritis
50
51 patients. However, the results should be cautiously interpreted considering the
52
53 heterogeneity and the fact that all studies are non-randomized and retrospective.
54
55
56
57
58 Further studies are needed to explore the mechanism and confounding factors
59
60

1
2
3
4 between *H. pylori* and osteoporosis.
5
6
7

8 9 **Funding**

10
11 This work was supported by the National Natural Science Foundation of China [No.
12
13 81202220 to Y. Z.; No. 81673211 and 81372952 to T. C.], by the Natural Science
14
15 Foundation of Jiangsu Province, China [No. BK20150094 to Q.Z.], and by the
16
17 Chongqing Health and Family Planning Commission [No. 20141027 to H. X.].
18
19
20
21

22 **Contributors**

23
24 YZ and HX led the study by designing, interpreting results, and revising manuscript
25
26 critically for important intellectual content; TW and XL contributed to data analysis,
27
28 result interpretation and drafting of the manuscript; QZ, BG and JZ participated in
29
30 study data collection and revising manuscript; TW, XL, TC and LY participated in
31
32 study conduct and results interpretation. All authors read and approved the final
33
34 manuscript.
35
36
37
38
39

40 **Competing interests**

41
42 The authors declare that they have no competing interests.
43
44

45 **Patient consent** Not required.
46
47

48 **Provenance and peer review** Not commissioned; externally peer reviewed.
49
50

51 **Data sharing statement** No additional data are available.
52
53
54
55
56
57
58
59
60

References

1. Zeng MD, Fan JG, Lu LG, et al. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. *J Dig Dis* 2008;9(2):108-12. doi: 10.1111/j.1751-2980.2008.00331.x [published Online First: 2008/04/19]
2. Lu L-j, Hao N-B, Liu J-J, et al. Correlation between Helicobacter pylori Infection and Metabolic Abnormality in General Population: A Cross-Sectional Study. *Gastroenterology research and practice* 2018
3. Ozaydin N, Turkyilmaz SA, Cali S. Prevalence and risk factors of Helicobacter pylori in Turkey: a nationally-representative, cross-sectional, screening with the (1)(3)C-Urea breath test. *BMC public health* 2013;13:1215. doi: 10.1186/1471-2458-13-1215 [published Online First: 2013/12/24]
4. Dorji D, Dendup T, Malaty HM, et al. Epidemiology of Helicobacter pylori in Bhutan: the role of environment and Geographic location. *Helicobacter* 2014;19(1):69-73. doi: 10.1111/hel.12088 [published Online First: 2013/10/10]
5. Eusebi LH, Zagari RM, Bazzoli F. Epidemiology of Helicobacter pylori infection. *Helicobacter* 2014;19 Suppl 1:1-5. doi: 10.1111/hel.12165 [published Online First: 2014/08/30]
6. den Hollander WJ, Holster IL, den Hoed CM, et al. Ethnicity is a strong predictor for Helicobacter pylori infection in young women in a multi-ethnic European city. *J Gastroenterol Hepatol* 2013;28(11):1705-11. doi: 10.1111/jgh.12315 [published Online First: 2013/07/03]
7. Pereira MI, Medeiros JA. Role of Helicobacter pylori in gastric mucosa-associated lymphoid tissue lymphomas. *World journal of gastroenterology* 2014;20(3):684-98. doi: 10.3748/wjg.v20.i3.684 [published Online First: 2014/02/28]
8. Bellos I, Daskalakis G, Pergialiotis V. Helicobacter pylori infection increases the risk of developing preeclampsia: A meta-analysis of observational studies. *Int J Clin Pract* 2018;72(2) doi: 10.1111/ijcp.13064 [published Online First: 2018/02/02]
9. Hou Y, Sun W, Zhang C, et al. Meta-analysis of the correlation between Helicobacter pylori infection and autoimmune thyroid diseases. *Oncotarget* 2017;8(70):115691-700. doi: 10.18632/oncotarget.22929 [published Online First: 2018/02/01]
10. Rahmani Y, Mohammadi S, Babanejad M, et al. Association of Helicobacter Pylori with Presence of Myocardial Infarction in Iran: A Systematic Review and Meta-Analysis. *Ethiopian journal of health sciences* 2017;27(4):433-40. [published Online First: 2017/12/09]
11. Wijarnpreecha K, Chesdachai S, Thongprayoon C, et al. Association of Helicobacter pylori with the Risk of Hepatic Encephalopathy. *Digestive diseases and sciences* 2017;62(12):3614-21. doi: 10.1007/s10620-017-4834-1 [published Online First: 2017/11/10]
12. Abdollahi A, Etemadian M, Shoar S, et al. Is Helicobacter pylori Infection a Risk Factor for Prostatitis? A Case-Control Study in a Referring Tertiary Care Center. *Iranian journal of pathology* 2016;11(4):323-27. [published Online First: 2017/09/01]
13. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. *The American journal of medicine* 1993;94(6):646-50. [published Online First: 1993/06/01]
14. Wu TY, Hu HY, Lin SY, et al. Trends in hip fracture rates in Taiwan: a nationwide study from 1996 to 2010. *Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA* 2017;28(2):653-65. doi: 10.1007/s00198-016-3783-4 [published

- 1
2
3 Online First: 2016/11/20]
4
5 15. Hernlund E, Svedbom A, Ivergard M, et al. Osteoporosis in the European Union: medical
6 management, epidemiology and economic burden. A report prepared in collaboration with the
7 International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical
8 Industry Associations (EFPIA). *Arch Osteoporos* 2013;8:136. doi:
9 10.1007/s11657-013-0136-1 [published Online First: 2013/10/12]
10
11 16. Asaoka D, Nagahara A, Shimada Y, et al. Risk factors for osteoporosis in Japan: Is it associated
12 with *Helicobacter pylori*? *Therapeutics and clinical risk management* 2015;11((Asaoka D.,
13 daisuke@juntendo.ac.jp; Nagahara A.; Shimada Y.; Matsumoto K.; Ueyama H.; Matsumoto
14 K.; Nakagawa Y.; Takeda T.; Tanaka I.; Sasaki H.; Osada T.; Hojo M.; Watanabe S.)
15 Department of gastroenterology, University of Juntendo, School of Medicine, Tokyo,
16 Japan):381-91. doi: 10.2147/tcrm.s80647
17
18 17. Yoshimura N, Suzuki T, Hosoi T, et al. Epidemiology of hip fracture in Japan: incidence and risk
19 factors. *Journal of bone and mineral metabolism* 2005;23 Suppl:78-80. [published Online
20 First: 2005/06/30]
21
22 18. Liu K, Liu P, Liu R, et al. Relationship between serum leptin levels and bone mineral density: a
23 systematic review and meta-analysis. *Clinica chimica acta; international journal of clinical*
24 *chemistry* 2015;444:260-3. doi: 10.1016/j.cca.2015.02.040 [published Online First:
25 2015/03/10]
26
27 19. Upala S, Sanguankeo A, Wijarnpreecha K, et al. Association between *Helicobacter pylori* infection
28 and osteoporosis: a systematic review and meta-analysis. *Journal of bone and mineral*
29 *metabolism* 2016;34(4):482-3. doi: 10.1007/s00774-015-0703-1 [published Online First:
30 2015/08/22]
31
32 20. Jaruvongvanich V, Upala S, Wijarnpreecha K, et al. Association between *helicobacter pylori* and
33 osteoporosis: A systematic review and meta-analysis. *American Journal of Gastroenterology*
34 2015;110((Jaruvongvanich V.) University of Hawaii, Internal Medicine Residency Program,
35 John A. Burns School of Medicine, Honolulu, HI, United States):S1021. doi:
36 10.1038/ajg.2015.281
37
38 21. Chinda D, Shimoyama T, Matsuzaka M, et al. *Helicobacter pylori* infection is not a risk for
39 osteopenia in Japanese healthy males. *American Journal of Gastroenterology*
40 2016;111((Chinda D.; Shimoyama T.; Fukuda S.) Department of Gastroenterology, Hirosaki
41 University, Graduate School of Medicine, Hirosaki, Aomori, Japan):S1289. doi:
42 10.1038/ajg.2016.390
43
44 22. Chinda D, Shimoyama T, Matsuzaka M, et al. Decrease of estradiol and several life style factors,
45 but not *helicobacter pylori* infection, are significant risks for osteopenia in Japanese females.
46 *American Journal of Gastroenterology* 2016;111((Chinda D.; Shimoyama T.; Fukuda S.)
47 Department of Gastroenterology, Hirosaki University, Graduate School of Medicine, Hirosaki,
48 Aomori, Japan):S499. doi: 10.1038/ajg.2016.363
49
50 23. Kalantarhormozi MR, Assadi M, Vahdat K, et al. *Chlamydia pneumoniae* and *Helicobacter pylori*
51 IgG seropositivities are not predictors of osteoporosis-associated bone loss: a prospective
52 cohort study. *Journal of bone and mineral metabolism* 2016;34(4):422-28. doi:
53 10.1007/s00774-015-0688-9
54
55 24. Zhang C, Guo L, Hou W, et al. Relationship between the interaction of gastric *helicobacter pylori*
56 infection and polymorphism of TLR4 gene G11367C and NADPH oxidase gene His72Tyr
57
58
59
60

- and the idiopathic osteoporosis in adults. *Chinese Journal of Osteoporosis* 2016;22(5):515-23.
25. Abdolahi N, Aghaei M, Naghdi M. Helicobacter pylori infection and osteoporosis in post menopausal women. *Annals of the Rheumatic Diseases* 2017;76((Abdolahi N.; Aghaei M.; Naghdi M.) Golestan Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran):1354. doi: 10.1136/annrheumdis-2017-eular.6445
26. Chinda D, Shimoyama T, Iino C, et al. Decrease of Estradiol and Several Lifestyle Factors, but Not Helicobacter pylori Infection, Are Significant Risks for Osteopenia in Japanese Females. *Digestion* 2017;96(2):103-09. doi: 10.1159/000479317
27. Pan BL, Huang CF, Chuah SK, et al. Relationship between Helicobacter pylori infection and bone mineral density: a retrospective cross-sectional study. *BMC Gastroenterol* 2018;18(1):54. doi: 10.1186/s12876-018-0780-4 [published Online First: 2018/04/28]
28. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6(7):e1000097. doi: 10.1371/journal.pmed.1000097 [published Online First: 2009/07/22]
29. Wright E, Schofield PT, Molokhia M. Bisphosphonates and evidence for association with esophageal and gastric cancer: a systematic review and meta-analysis. *BMJ open* 2015;5(12):e007133. doi: 10.1136/bmjopen-2014-007133 [published Online First: 2015/12/09]
30. Ottawa Hospital Research Institute, "The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses," 2011, http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
31. Deeks JJ, Higgins JP, Altman DG, et al. Analysing data and undertaking meta-analysis; in Higgins JP (ed.): *Cochrane Handbook for systematic Reviews of Interventions*. Chichester, The Cochrane Collaboration 2008: 243–296
32. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315(7109):629-34. [published Online First: 1997/10/06]
33. Mizuno S, Matsui D, Watanabe I, et al. Serologically Determined Gastric Mucosal Condition Is a Predictive Factor for Osteoporosis in Japanese Men. *Digestive diseases and sciences* 2015;60(7):2063-69. doi: 10.1007/s10620-015-3576-1
34. Fotouk-Kiai M, Hoseini SR, Meftah N, et al. Relationship between Helicobacter pylori infection (HP) and bone mineral density (BMD) in elderly people. *Caspian journal of internal medicine* 2015;6(2):62-66.
35. Chung YH, Gwak JS, Hong SW, et al. Helicobacter pylori: A Possible Risk Factor for Bone Health. *Korean journal of family medicine* 2015;36(5):239-44. doi: 10.4082/kjfm.2015.36.5.239 [published Online First: 2015/10/06]
36. Asaoka D, Nagahara A, Shimada Y, et al. Risk factors for osteoporosis-are infection or eradication of helicobacter pylori associated? *Gastroenterology* 2015;148(4):S337-S38.
37. Lin SC, Koo M, Tsai KW. Association between helicobacter pylori infection and risk of osteoporosis in elderly Taiwanese women with upper gastrointestinal diseases: A retrospective patient record review. *Gastroenterology research and practice* 2014;2014((Lin S.-C., t780927t@yahoo.com.tw; Tsai K.-W., cktsai@aol.com) Department of Geriatrics, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, 2 Minsheng Road, Dalin, Chiayi 62247, Taiwan) doi: 10.1155/2014/814756
38. Asaoka D, Nagahara A, Shimada Y, et al. H.pylori infection is a risk factor of osteoporosis in Japan.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Gastroenterology* 2014;146(5):S-504. doi: 10.1016/s0016-5085(14)61821-7
39. Asaoka D, Nagahara A, Hojo M, et al. The Relationship between H-pylori Infection and Osteoporosis in Japan. *Gastroenterology research and practice* 2014
40. Chinda D, Shimoyama T, Matsuzaka M, et al. Assessment of the association between helicobacter pylori infection and osteopenia in japanese healthy adults. *Helicobacter* 2013;18((Chinda D.; Shimoyama T.; Matsuzaka M.; Nakaji S.; Fukuda S.) Hirosaki University Graduate, School of Medicine, Hirosaki, Japan):114. doi: 10.1111/hel.12079
41. Akkaya N, Akkaya S, Polat Y, et al. Helicobacter Pylori Seropositivity in Patients with Postmenopausal Osteoporosis. *Journal of Physical Therapy Science* 2011;23(1):61-64.
42. Kakehasi AM, Rodrigues CB, Carvalho AV, et al. Chronic gastritis and bone mineral density in women. *Digestive diseases and sciences* 2009;54(4):819-24. doi: 10.1007/s10620-008-0417-5 [published Online First: 2008/08/08]
43. Kakehasi AM, Mendes CMC, Coelho LGV, et al. The presence of Helicobacter pylori in postmenopausal women is not a factor to the decrease of bone mineral density. *Arquivos de gastroenterologia* 2007;44(3):266-70.
44. Figura N, Gennari L, Merlotti D, et al. Prevalence of Helicobacter pylori infection in male patients with osteoporosis and controls. *Digestive diseases and sciences* 2005;50(5):847-52. doi: 10.1007/s10620-005-2651-4
45. Noach LA, Bosma NB, Jansen J, et al. Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. *Scand J Gastroenterol* 1994;29(5):425-9. [published Online First: 1994/05/01]
46. Kalkan C, Karakaya F, Tuzun A, et al. Factors related to low serum vitamin B12 levels in elderly patients with non-atrophic gastritis in contrast to patients with normal vitamin B12 levels. *Geriatrics & gerontology international* 2016;16(6):686-92. doi: 10.1111/ggi.12537 [published Online First: 2015/06/06]
47. Tucker KL, Hannan MT, Qiao N, et al. Low plasma vitamin B12 is associated with lower BMD: the Framingham Osteoporosis Study. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research* 2005;20(1):152-8. doi: 10.1359/JBMR.041018 [published Online First: 2004/12/28]
48. Wijarnpreecha K, Thongprayoon C, Panjawatnan P, et al. Helicobacter pylori and Risk of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. *Journal of clinical gastroenterology* 2018;52(5):386-91. doi: 10.1097/MCG.0000000000000784 [published Online First: 2017/01/19]
49. Upala S, Jaruvongvanich V, Wijarnpreecha K, et al. Nonalcoholic fatty liver disease and osteoporosis: a systematic review and meta-analysis. *Journal of bone and mineral metabolism* 2017;35(6):685-93. doi: 10.1007/s00774-016-0807-2 [published Online First: 2016/12/09]

1
2
3
4 Figure legend
5
6
7
8

9 Figure 1. Flow diagram of the article selection for systematic review.
10

11 Figure 2. Forest plot of the included studies assessing the association between
12 *Helicobacter pylori* and osteoporosis (random effects models). CI indicates
13 confidence interval.
14
15
16
17
18

19 Figure 3. Forest plot of cumulative meta-analysis.
20

21 Figure 4. Forest plot of subgroup meta-analysis according to diagnosis (random
22 effects models).
23
24
25

26 Figure 5. Funnel plot of publication bias for the association between *Helicobacter*
27 *pylori* and osteoporosis.
28
29
30

31 Figure 6. The Egger's test for publication bias.
32
33
34
35
36

37 Supplementary figure 1. Meta-analysis of SMD according to detection locations.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Characteristics and quality assessment of the studies included

| Author [Reference] | Year | Country | Sex(M/F) | Age(mean age±SD or (range age) years) | Detection method of <i>H.pylori</i> | Detection methods of osteoporosis | Diagnosis locations | Diagnosis | Cases/Controls/ Total | Scores of NOS | Main adjusted factors (the methods used for adjusting) |
|-------------------------------------|------|---------|----------------------|--|-------------------------------------|-----------------------------------|-----------------------|--------------|-----------------------|---------------|---|
| Figura, N. ⁴⁴ | 2005 | Italy | Males | 65 (55–82) for patients; 64.5(55–80) for controls | ELISA | DEXA | Lumbar and femur bone | Osteoporosis | 80/160/240 | 7 | age, socioeconomic background, and smoking habits. |
| Adriana M. KAKEHASI ⁴³ | 2007 | Brazil | Postmenopausal women | 61.6±7(50–79) | non-ELISA | DEXA | Lumbar spine | Osteoporosis | 18/32/50 | 6 | mean age, body mass index, age at menarche, postmenopausal period |
| Adriana M. Kakehasi ^{42,#} | 2009 | Brazil | Postmenopausal women | 63.7±7.3 for Hp(+) 62.5±7.0 for Hp(-) | non-ELISA | DEXA | Lumbar spine and hip | Not fitted* | 34/27/61 | - | age, Postmenopausal time, BMI |
| Akkaya, Nuray ⁴¹ | 2011 | Turkey | Postmenopausal women | 65.29±6.09 patients; 63.57±6.53 controls | ELISA | DEXA | Lumbar and femur neck | Osteoporosis | 58/47/105 | 6 | age, education level, occupation, age of menarche or menopause, duration of postmenopausal, period or daily consumption of tea, coffee, alcohol or dairy products |
| Chinda, D. ⁴⁰ | 2013 | Japan | 379/631 | not mentioned | ELISA | QU | Calcaneal osteo | Osteopenia | -/-/1010 | 7 | age, BMI, smoking, alcohol consumption, periodical exercise, latest educational level (logistic regression analysis) |
| Asaoka, Daisuke ³⁹ | 2014 | Japan | 95/105 | 63.1±8.8 years | Both | DEXA | Lumbar vertebrae | Osteoporosis | 41/159/200 | 6 | age, gender, BMI, alcohol consumption, smoking, BAP, PUD, and EGA (multivariate logistic regression analysis) |
| Asaoka, D. ³⁸ | 2014 | Japan | 131/26 | 71.1±7.5 patients 61.6±8.9 controls | not mentioned | DEXA | Lumbar | Osteoporosis | 24/133/157 | 6 | age, sex, BMI, Brinkman Index (B.I.), accumulated amount of alcohol (multivariate analysis) |
| Lin, S. C. ³⁷ | 2014 | China | Female | 77 (65–97) | non-ELISA | DEXA | Not mentioned | Osteoporosis | 101/264/365 | 5 | age group, body mass index group, and use of proton pump inhibitor (multivariate logistic regression analyses) |
| Asaoka, D. ³⁶ | 2015 | Japan | 130/134 | 69.8±6.8 for patients 61.9±8.2 for controls | not mentioned | DEXA | Not mentioned | Osteoporosis | 45/219/264 | 7 | age, sex, BMI. etc (multivariate analysis) |
| Asaoka, D. ¹⁶ | 2015 | Japan | 120/135 | 63.2±8.5 | Both | DEXA | Lumbar vertebrae | Osteoporosis | 43/212/255 | 6 | age, sex, BMI, cumulative alcohol intake, Brinkman index, type 2 diabetes mellitus, calcium channel blocker, PPI, hemoglobin, calcium, gamma glutamyl transpeptidase, bone-specific alkaline phosphatase, NTX, hiatal hernia, and EGA (multivariate logistic regression analysis) |
| Chung, Y. H. ^{35,#} | 2015 | Korea | Men | 54.4±10.7 for Hp+ 51.9±12.1 for Hp- | ELISA | DEXA | Lumbar (L1–L4) | osteopenia | -/-/1126 | 7 | Height, weight, BMI, alcohol, exercise. |
| Fotouk-Kiai, M. ^{34,#} | 2015 | Iran | 575/392 | 68.3±6.8 for hp+ 69.3±7.4 for hp- | ELISA | DEXA | Lumbar vertebra | Osteoporosis | 314/653/967 | 5 | age, sex, smoking, alcohol consumption and BMI |

| | | | | | | | | and Femur | | | | |
|----|--|------|----------|----------------------|---|-----------|---------------|------------------------|---------------|--------------|---|--|
| 1 | | | | | | | | | | | | |
| 2 | | | | | | | | | | | | |
| 3 | Mizuno, S. ³³ | 2015 | Japanese | Men | 62.1±5.0 for low TBD 58.4±5.7 for normal | ELISA | QU | Not mentioned | Decreased BMD | 116/114/230 | 8 | Age, BMI and smoking habit (logistic regression analysis) |
| 4 | | | | | | | | | | | | |
| 5 | | | | | | | | | | | | |
| 6 | Chinda, D. ²¹ | 2016 | Japan | Men | 50.2±15.4 years | ELISA | QU | Not mentioned | Osteopenia | -/-/295 | 7 | age, BMI, serum level of estradiol, the intake of calcium per day, smoking, drinking, periodical exercise, last educational background (logistic regression) |
| 7 | | | | | | | | | | | | |
| 8 | | | | | | | | | | | | |
| 9 | | | | | | | | | | | | |
| 10 | Chinda, D. ²² | 2016 | Japan | Females | 52.2±15.2 | ELISA | QU | Not mentioned | Osteopenia | -/-/473 | 6 | age, BMI, smoking, alcohol consumption, periodical exercise, last educational level, serum level of estradiol, calcium intake per day (multiple logistic regression) |
| 11 | | | | | | | | | | | | |
| 12 | | | | | | | | | | | | |
| 13 | Kalantarhormozi, M. R. ^{23,#} | 2016 | Iran | Postmenopausal women | 58.87±8.02 | ELISA | DEXA | lumbar spine and femur | Osteoporosis | 16/234/250 | 6 | age and BMI (multiple linear regression) |
| 14 | | | | | | | | | | | | |
| 15 | | | | | | | | | | | | |
| 16 | Zhang, Chaoxian ²⁴ | 2016 | China | 194/126 | 38.32±10.64 for patients 38.27±7.46 for controls | non-ELISA | DEXA | Not mentioned | Osteoporosis | 160/160/320 | 5 | Age, gender, gene (multiple logistic regression) |
| 17 | | | | | | | | | | | | |
| 18 | | | | | | | | | | | | |
| 19 | Abdolahi, N. ²⁵ | 2017 | Iran | Postmenopausal women | not mentioned | ELISA | not mentioned | Not mentioned | Osteoporosis | 73/34/107 | 8 | not mentioned |
| 20 | | | | | | | | | | | | |
| 21 | | | | | | | | | | | | |
| 22 | Chinda, D. ²⁶ | 2017 | Japan | Females | 62.5±8.6 for patients 44.9±10.9 for controls | ELISA | QU | Calcaneus | Osteopenia | 197/276/473 | 4 | age, smoking and drinking habit, schooling duration, estradiol levels, menopause, birth history (multiple logistic regression analysis) |
| 23 | | | | | | | | | | | | |
| 24 | | | | | | | | | | | | |
| 25 | Lu, Li-juan ² | 2018 | China | 1474/393 | 54.0±9.6 | non-ELISA | QU | Calcaneus | Osteoporosis | 900/967/1867 | 6 | gender and age |
| 26 | | | | | | | | | | | | |
| 27 | | | | | | | | | | | | |
| 28 | Pan, B. L. ²⁷ | 2018 | China | 568/299 | 55.9±11.3 | non-ELISA | DEXA | Not mentioned | Decreased BMD | 311/556/867 | 5 | Sex, age, BMI, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and peptic ulcer disease (multiple stepwise logistic regression analyses) |
| 29 | | | | | | | | | | | | |
| 30 | | | | | | | | | | | | |

Not fitted *: this study only explored the alteration of BMD in patients with *H. pylori* infection.

#: this study also reported the BMD in patients with *H. pylori* infection.

ELISA: enzyme linked immunosorbent assay; QU: quantitative ultrasound; DEXA: dual energy X-ray absorptiometry scan; NOS : Newcastle-Ottawa scale

Table 2. Overall effect estimates for *Helicobacter pylori* infection and osteoporosis according to study characteristics

| Factors | Categories | No. of studies | OR [95%CI] | Model used | Heterogeneity | | Meta-regression | |
|---------------------------------------|--------------------------|----------------|------------------|------------|----------------|---------|-----------------|---------|
| | | | | | I ² | P-value | t | P-value |
| Sex* | Female | 8 | 1.09(0.87,1.35) | Fixed | 33.0% | 0.17 | - | - |
| | Male | 5 | 1.27(1.07,1.50) | Fixed | 14.6% | 0.32 | 0.47 | 0.64 |
| | Both | 9 | 1.21(1.07,1.37) | Random | 85.6% | 0.00 | 1.78 | 0.09 |
| Postmenopausal or not | Non-postmenopausal women | 4 | 1.08 (0.83,1.41) | Fixed | 48.0% | 0.12 | - | - |
| | Postmenopausal women | 4 | 1.09(0.75,1.58) | Fixed | 35.8% | 0.20 | -0.13 | 0.90 |
| Country | China | 4 | 1.86(1.06,3.28) | Random | 90.4% | 0.00 | - | - |
| | Japan | 9 | 1.57(1.08,2.28) | Random | 63.7% | 0.005 | -0.39 | 0.70 |
| | Italy | 1 | 0.87(0.50,1.53) | | - | - | -1.11 | 0.29 |
| | Brazil | 1 | 0.42(0.12,1.42) | | - | - | -1.69 | 0.11 |
| | Korea | 1 | 1.29(1.05,1.57) | | - | - | -0.59 | 0.57 |
| | Iran | 3 | 1.06(0.60,1.86) | Random | 61.3% | 0.075 | -1.16 | 0.27 |
| | Turkey | 1 | 0.95(0.53,1.69) | | - | - | -0.98 | 0.34 |
| Asian country or not | Non-Asian country | 2 | 0.77(0.46,1.28) | Fixed | 12.8% | 0.28 | - | - |
| | Asian country | 18 | 1.44(1.16,1.79) | Random | 73.9% | 0.00 | 1.60 | 0.13 |
| Detection methods of <i>H. pylori</i> | ELISA | 11 | 1.09(0.96,1.24) | Fixed | 32.1% | 0.14 | - | - |
| | Non-ELISA | 5 | 1.62(0.96,2.72) | Random | 88.4% | 0.00 | 1.52 | 0.15 |
| | Both | 2 | 3.67(1.88, 7.16) | Fixed | 0% | 0.42 | 2.65 | 0.02 |
| Detection methods of osteoporosis | DEXA | 13 | 1.58(1.14,2.18) | Random | 79.5% | 0.00 | - | - |
| | QU | 6 | 1.05(0.90,1.22) | Fixed | 0% | 0.51 | -1.33 | 0.20 |
| Detection location of DEXA | | | | | | | | |

| | | | | | | | |
|--------|---|-----------------|--------|-------|-------|-------|------|
| Lumbar | 6 | 1.75(0.99,3.07) | Random | 65.4% | 0.013 | - | - |
| Femur | 3 | 1.56(1.17,2.08) | Fixed | 0% | 0.90 | -0.17 | 0.87 |

*: One study has both males, females and over results, it was used three times in subgroups analysis (males, females, and both).

ELISA: enzyme linked immunosorbent assay; QU: quantitative ultrasound; DEXA: dual energy X-ray absorptiometry scan.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Fig 1

199x194mm (300 x 300 DPI)




Fig 2

279x228mm (300 x 300 DPI)




Fig 3

281x240mm (300 x 300 DPI)




Fig 4

282x248mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Fig 5

79x60mm (300 x 300 DPI)




28
29

Fig 6

30
31
32

152x101mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



277x215mm (300 x 300 DPI)

PRISMA Checklist

| Section/topic | # | Checklist item | Reported on page # |
|------------------------------------|----|---|--------------------|
| TITLE | | | |
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both. | 1 |
| ABSTRACT | | | |
| Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 2 |
| INTRODUCTION | | | |
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. | 3 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 4 |
| METHODS | | | |
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | NA |
| Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 6 |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 6 |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | 6 |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 6 |
| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 6 |
| Data items | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | 7 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | 7 |
| Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means). | 8 |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I ²) for each meta-analysis. | 8 |

PRISMA Checklist

| Section/topic | # | Checklist item | Reported on page # |
|-------------------------------|----|--|--------------------|
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | 8 |
| Additional analyses | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | 8 |
| RESULTS | | | |
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | 9 |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | 9 |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | 10 |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. | NA |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | 10 |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15). | 11 |
| Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). | 12 |
| DISCUSSION | | | |
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). | 12 |
| Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | 15 |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research. | 16 |
| FUNDING | | | |
| Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | 17 |

BMJ Open

Relationship between *Helicobacter pylori* infection and osteoporosis: A systematic review and meta-analysis

| | |
|---------------------------------|--|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2018-027356.R2 |
| Article Type: | Research |
| Date Submitted by the Author: | 24-Apr-2019 |
| Complete List of Authors: | Wang, Taiwu; Third Military Medical University, Department of Epidemiology Li, Xiang; The Southwest Medical University, School of pharmacy Zhang, Qi; Center for Disease Control and Prevention of Eastern Theater Command Ge, Bingjie; 95810 Unit, The Chinese People's Liberation Army Zhang, Jinhai; Center for Disease Control and Prevention of Eastern Theater Command Yu, Lei; Third Military Medical University, Department of Epidemiology Cai, Tongjian; Third Military Medical University, Department of Epidemiology Zhang, Yao Xiong, Hongyan |
| Primary Subject Heading: | Epidemiology |
| Secondary Subject Heading: | Infectious diseases, Epidemiology |
| Keywords: | osteoporosis, bone mineral density, <i>Helicobacter pylori</i> , meta-analysis |
| | |

SCHOLARONE™
Manuscripts

Original article

Relationship between *Helicobacter pylori* infection and osteoporosis:

A systematic review and meta-analysis

Running Title: Relationship between *H. pylori* and osteoporosis

Taiwu Wang^{1,2,*}, Xiang Li^{3,*}, Qi Zhang², Bingjie Ge⁴, Jinhai Zhang², Lei Yu¹, Tongjian Cai¹, Yao Zhang^{1,†}, Hongyan Xiong^{1,†}

¹ Department of Epidemiology, College of Preventive Medicine, Third Military Medical University, Chongqing 400038, People's Republic of China.

² Center for Disease Control and Prevention of Eastern Theater Command, Nanjing 210002, People's Republic of China.

³ School of pharmacy, The Southwest Medical University, Luzhou 646000, People's Republic of China.

⁴ 95810 Unit, The Chinese People's Liberation Army, Beijing 100076, People's Republic of China.

* These authors contributed equally to this work.

† These authors jointly supervised this work.

Corresponding author's information: Yao Zhang(sydzzy2003@sina.com),

Hongyan Xiong(hongyanxiong@126.com);

Address: Gaotanyan Road 30, Shapingba District, Chongqing 400038, China.

Word count: 3328

Abstract

Objectives Many studies have explored the association between *Helicobacter pylori* (*H. pylori*) infection and osteoporosis. However, the results remain controversial. Therefore, we performed this systematic review and meta-analysis to evaluate the association between *H. pylori* infection and osteoporosis.

Design Systematic review and meta-analysis of case-control studies.

Data sources Databases, including PubMed, Embase, Web of Science and CBM, were screened from inception to April 30, 2018.

Eligibility Criteria Case-control studies aimed at assessing the association between *H. pylori* infection and osteoporosis.

Data extraction and analysis Study characteristics and study quality sections were reviewed. Studies were selected, and data were extracted by two reviewers. Pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated using random effects model if heterogeneity existed, otherwise fixed effects model was used. Subgroup analyses were performed to explore the source of heterogeneity. Publication bias and sensitivity analyses were also tested.

Results A total of 21 studies with 9655 participants were included in our analyses. Taking together, we found that *H. pylori* infection was associated with increased odds of osteoporosis (OR (95%CI): 1.39(1.13–1.71)); there was no significant difference between osteoporosis and osteopenia; the association between osteoporosis and *H. pylori* infection was relatively higher in males than females, but didn't reach significant level. However, the decrease of bone mineral density in *H. pylori* positive

1
2
3
4 patients was not significant when compared with *H. pylori* negative controls, which
5
6 may due to the sample size.
7

8
9 **Conclusions** Our meta-analysis suggests an association between osteoporosis and
10
11 *Helicobacter pylori* infection. The clinicians should pay more attention to the patients
12
13 infected with *H. pylori*. Further studies were still needed to exploring the confounding
14
15 factors among studies and to elucidate the underlying biological mechanisms.
16
17

18
19 **Keywords:** osteoporosis; bone mineral density; *Helicobacter pylori*; meta-analysis.
20
21
22
23
24
25
26
27
28
29

30 **Strengths and limitations of this study**

- 31
32
33 ▶ 21 studies with conflicting results were included for testing the association between
34
35 osteoporosis and *Helicobacter pylori* infection.
36
37
38 ▶ This is the third and most comprehensive meta-analysis, bringing the overall results
39
40 of statistical significance and increased odds.
41
42
43 ▶ The results of the meta-analysis should be interpreted with caution due to the
44
45 number and quality of studies included, and obvious heterogeneity.
46
47
48 ▶ Causality can't be established in observational study as the chronological order
49
50 between *Helicobacter pylori* infection and osteoporosis can't be confirmed.
51
52
53
54
55
56
57
58
59
60

Introduction

Helicobacter pylori (*H. pylori*), a Gram-negative and spiral-shaped bacterium dwelling on the gastric epithelium, has an influence on approximately 50% of the global population, especially those living in developing countries¹. The prevalence of *H. pylori* infection is approximately 30% in developed countries and up to 80% in developing countries^{2,3}, and up to 90% in patients with dyspepsia⁴. In North Europe and North America, about one-third of adults are infected, and in South and East Europe, South America, and Asia, the prevalence of *H. pylori* is often higher than 50%⁵. Moreover, infected subjects born abroad (first-generation immigrants) had a higher risk of *H. pylori* infection than second-generation immigrants in a multi-ethnic European city⁶. *H. pylori* has been well-known to be associated with gastrointestinal diseases, such as gastritis, gastric ulcer, stomach cancer and so on⁷. Furthermore, some non-gastrointestinal diseases have also been proven to be associated with *H. pylori* by large-scale population researches or meta-analysis, such as preeclampsia⁸, autoimmune thyroid diseases⁹, myocardial infarction¹⁰, hepatic encephalopathy¹¹ and prostatitis¹².

Osteoporosis is one of the most common metabolic bone diseases, characterized by decreased bone mineral density (BMD), increased bone fragility, and then increased susceptibility to fracture¹³, especially in spine and hip. Osteoporosis has become a major health concern for both individuals and societies. Osteoporosis has huge adverse impacts on life quality and is associated with increased morbidity rates. The in-hospital mortality rate is between 0.85 to 2.26%¹⁴. In Europe, about half of women

1
2
3
4 and one-fifth of men aged over fifty years develop pathological fractures in hip, spine,
5
6 forearm, or humerus due to osteoporosis during their remaining lifetime¹⁵. The same
7
8 situation happens in other countries or districts, such as Japan and Taiwan^{16 17}.

9
10
11 There are well established evidence regarding the risk factors for osteoporosis ¹⁷, such
12
13 as age, sex, body mass index (BMI), alcohol, and smoking. *H. pylori* infection can
14
15 induce inflammatory and immune responses, such as increasing the level of IL-1 and
16
17 TNF- α , which could trigger bone resorption, and regulate bone regeneration¹⁸.
18
19 Recently, many studies about the association between osteoporosis and *H. pylori* have
20
21 been performed. However, the role of *H. pylori* in osteoporosis remains controversial.
22
23 This issue has been discussed in previous meta-analysis ^{19 20}, but no significant
24
25 association was found. As more studies evaluating the association between *H. pylori*
26
27 infection and osteoporosis have been published since then ^{2 21-27}, we carried out this
28
29 updated meta-analysis to further evaluate the association between *H. pylori* infection
30
31 and osteoporosis qualitatively, and the quantitative alterations of BMD in *H. pylori*
32
33 infected patients compared with those in healthy controls.
34
35
36
37
38
39
40
41
42
43
44
45

46 **Materials and Methods**

47
48 This study was reported based on preferred reporting items for systematic reviews and
49
50 meta-analyses (PRISMA)²⁸. Study searching and selection, quality assessment, and
51
52 data extraction were done by two researchers (TW and XL) independently to avoid
53
54 bias, and disagreements were discussed by the two reviewers and by seeking the
55
56 opinion of the third author (YZ) if necessary.
57
58
59
60

Search strategy

We searched through the databases of PubMed, Embase, Web of Science and Chinese Biomedical Literature Database (CBM). The last search for all databases was updated to April 30, 2018. We used the combined method of MeSH Term and free words by applying the following terms: *Helicobacter pylori*, *campylobacter pylori*, *H. pylori*, *hp*, *helicobacter*, *helicobacter bill*, *helicobacter hepaticus*, *helicobacter pullorum*, *helicobacter species*, *helicobacter sp*, *helicobacter genus*, *campylobacter*, *campylobacter infection*, *campylobacteriosis*, *Helicobacter pylori infection*, *Helicobacter infection*, *pylori*, *enterohepatic helicobacter spp*, *campylobacter sp* and fragility fracture, bone density, bone mass density, osteocalcin, bone loss, osteoporosis. The search strategy is presented in the Appendix S1. Two authors evaluated potential publications by checking their titles and abstracts and then procured the most relevant publications for further examination. Bibliographies section of retrieved articles were also reviewed for additional pertinent studies which were possibly missed in the initial search.

Studies selection and data extraction

Studies were included if they met the following criteria: (1) it is an observational study; (2) its objective is to assess the association between *H. pylori* infection and osteoporosis, or compare the alteration of BMD between *H. pylori* positive and negative participants; (3) they either provided odds ratios (ORs) and 95% confidence intervals (95% CIs), or sufficient information was available to calculate the ORs and 95% CIs, or BMD in both *H. pylori* positive and negative participants. Articles were

1
2
3
4 excluded if they were duplicate publications, reviews, animal studies, editorials, or
5
6 case reports. The papers were also excluded if no effect estimate was reported or not
7
8 enough raw data for ORs and 95% CIs calculation was available. In the case of
9
10 multiple studies with the same or overlapping data published by the same researchers,
11
12 we selected the most recent study with the largest number of participants. All papers
13
14 meeting the criteria defined above were included for further analysis.
15
16
17

18
19 The literatures included were carefully reviewed for information about the first author,
20
21 publication year, country, population, sample size, sex, age, detection methods of *H.*
22
23 *pylori* and osteoporosis, diagnosis location, diagnosis, and adjusted covariates.
24
25

26
27 If data could be acquired from the tabulated literature search results, they would be
28
29 extracted carefully into 2x2 tables from all eligible publications by two independent
30
31 reviewers. If data were not directly available, they would be calculated from
32
33 published positive predictive values and/or negative predictive values if appropriate.
34
35

36
37 The adjusted OR (95%CI), if existed, was adopted instead of crude OR (95%CI)²⁹. In
38
39 addition, for the studies comparing the BMD of participants with and without *H.*
40
41 *pylori* infection, the data on BMD was also extracted.
42
43
44

45 **Quality assessment**

46
47
48 Quality assessment was performed using the Newcastle-Ottawa quality assessment
49
50 scale (NOS)³⁰. Two researchers conducted blinded quality assessment of the included
51
52 literatures. The NOS assigns a maximum of 9 points to studies of highest quality
53
54 according to three quality parameters: selection, comparability, and outcome.
55
56
57

58 **Statistical analyses**

1
2
3
4 The primary measures were ORs and 95% CIs for the association between *H. pylori*
5
6 infection and osteoporosis, and standardized mean difference (SMD) for BMD
7
8 alterations between *H. pylori* positive and negative participants. To assess
9
10 heterogeneity among the studies, we calculated the Cochran's Chi-squared test (with
11
12 $P < 0.10$ indicating statistically significant heterogeneity) and the statistic I^2 (The
13
14 heterogeneity might not be important with I^2 of 0 to 40%, while moderate
15
16 heterogeneity with I^2 of 30 to 60%, substantial heterogeneity with I^2 of 50 to 90% and
17
18 considerable heterogeneity with I^2 of 75 to 100%)³¹. The pooled results were
19
20 calculated using fixed effects model (Inverse Variance) if no obvious heterogeneity
21
22 existed, otherwise random effects model (I-V heterogeneity) was used ($P < 0.10$ was
23
24 considered indicative of obvious heterogeneity). The cumulative meta-analysis was
25
26 conducted for the extracted data using a pooled random effects model with the
27
28 publication year to confirm whether the effect size was affected by sample size or not.
29
30 In the event of obvious heterogeneity, subgroup analysis was performed according to
31
32 sex, postmenopausal or not, country, Asian or not, detection methods of *H. pylori*,
33
34 detection methods of osteoporosis, and detection location of dual-energy X-ray
35
36 absorptiometry (DEXA). Meta regression (using ReML methods) was also performed
37
38 to explore the potential heterogeneity. Publication bias was assessed by funnel plot
39
40 and Egger's test³². A sensitivity analysis was completed by converting the pooled
41
42 results from random effects model into fixed effects model or from fixed effects
43
44 model into random effects model. All statistical analyses were performed using Stata
45
46
47
48
49
50
51
52
53
54
55
56
57
58 12.0.
59
60

Patient and public involvement

There was no patient and public involvement as this was a database research study.

Results

Search results

Using our search strategy, a total of 1720 articles were identified through PubMed, Web of Science, Embase and CBM, and one additional record was identified through other sources. Then, 443 duplicate papers were removed firstly, and 1242 papers were excluded after scanning their titles and abstracts. After screening the full texts of the included articles, 15 studies were excluded for the following reasons: duplicate publication(n=4), not about the topic(n=2), no related data about *H. pylori* and/or osteoporosis(n=4), lack of access to full text (n=5). A total of 21 studies^{2 16 21-27 33-44} were included for further analysis (Figure 1).

Study Characteristics

A total of 21 articles were included in this study. Of the 21 articles included, 20 provided data for association between *H. pylori* and osteoporosis^{2 16 21-27 33-41 43 44}, 4 for the BMD alterations in *H. pylori* positive participants compared with negative controls^{23 34 35 42}, 3 provided both^{23 34 35}. All these studies were published from 2005 to 2018. Four studies were conducted in China, 3 in Iran, 1 in Italy, 9 in Japan, 2 in Brazil, 1 in Korea and 1 in Turkey. As to the sex of participants, 4 were postmenopausal women, 4 were females, 4 were males, 9 involved both males and females. The detection methods of *H. pylori* were mainly ELISA and ¹³C-urea breath test, while the detection methods of osteoporosis were DEXA and quantitative

1
2
3
4 ultrasound. As to the diagnosis, 5 were osteopenia, 13 were osteoporosis, and 2
5
6 provided decreased BMD (treated as osteopenia for analysis) (Table 1). In addition,
7
8
9 12 studies showed no significant associations of *H. pylori* infection and osteoporosis
10
11 (or osteopenia), while 8 showed significant associations.
12

13 14 **Quality evaluation**

15
16
17 The Newcastle-Ottawa scale (NOS) was adopted to evaluate the quality of these
18
19 case-control studies. Among the selection items, the evaluation results ranged from 4
20
21 to 8, with the median NOS score was 6, indicating a medium quality of the studies
22
23 included. The most common source of bias came from selection and comparability.
24
25 (Table 1)
26
27
28

29 30 **Synthesis of the results**

31
32 As shown in Figure 2, the overall OR was obtained based on the 20 studies involving
33
34 the *H. pylori* and osteoporosis (including osteopenia) (a total of 8788 patients and
35
36 healthy controls). As the existence of obvious heterogeneity (Chi-square = 69.60, $I^2 =$
37
38 72.7%, $P < 0.01$), random effect model was used and the pooled results of OR and its
39
40 95%CI were 1.37(1.11,1.69), indicating *H. pylori* infection was significantly
41
42 associated with increased odds of osteoporosis/osteopenia. A cumulative
43
44 meta-analysis was conducted with publication year in ascending order, and the results
45
46 indicated that the pooled OR (95% CI) started to show statistical significance at 1.57
47
48 (95% CI: 1.02,2.41) from the ninth analyzed study, with gradually stabilizing results
49
50 afterwards (Figure 3).
51
52
53
54
55
56
57

58 59 **Subgroup analyses**

60

1
2
3
4 Given that obvious heterogeneity existed, subgroup analyses were performed based
5
6 on the potential confounding factors. All 20 studies were involved in these subgroup
7
8 analyses. Figure 4 showed that both osteoporosis and osteopenia were significantly
9
10 associated with *H. pylori* infection with OR(95%CI) of 1.61(1.11, 2.32) and 1.22(1.07,
11
12 1.39) respectively. Although the OR was a little higher in osteoporosis group, the
13
14 meta regression analysis showed no significant difference between these two groups
15
16 ($t=1.18$, $P=0.26$). Therefore, we pooled osteoporosis and osteopenia together to
17
18 analyze other confounding factors.
19
20
21
22
23

24 Results of subgroup analyses by other factors were shown in Table 2. We found that
25
26 the association between *H. pylori* infection and osteoporosis was significant in males
27
28 and both sexes, but not in females. However, meta regression analysis showed no
29
30 significant difference between these two groups. Moreover, no significant
31
32 associations between *H. pylori* infection and osteoporosis were observed in either the
33
34 postmenopausal women or non-postmenopausal women subgroup. When stratified by
35
36 countries, we found significant associations between *H. pylori* infection and
37
38 osteoporosis in China, Japan, and Korea (three East Asian countries). Other factors
39
40 that may affect the results were presented in Table 2.
41
42
43
44
45
46
47

48 **Publication bias and sensitivity analyses**

49

50 Funnel plot was used to examine the publication bias of this meta-analysis. As shown
51
52 in Figure 5, the funnel plot indicated no publication bias, which was also confirmed
53
54 by Egger's test, with t of 1.57 and P of 0.13 in Figure 6. Sensitivity analysis was also
55
56 performed by converting the pooled model from the random effects model to the fixed
57
58
59
60

1
2
3
4 effects model. The result of fixed effects model was 1.21(1.10-1.33), showed no
5
6 obvious differences compared with the result of random effects model, indicating the
7
8 pooled results was relatively stable.
9
10

11 **Alterations of BMD in *H. pylori* infected population**

12
13
14 Four studies were involved in this meta-analysis^{23 34 35 42}. As each study included for
15
16 this analysis has two different DEXA detection locations, we carried out the subgroup
17
18 analysis based on detection locations, and the patients are not being counted twice in
19
20 each subgroup. In addition, we chose standardized mean difference as pooled
21
22 outcome for the detection methods varied with studies. As shown in Appendix S2, the
23
24 BMD(g/cm²) alterations between *H. pylori* positive and negative participants were
25
26 -0.01(-0.45,0.42) for hip, -0.94(-3.15,1.28) for lumber and -0.04(-0.40,0.31) for femur
27
28 using random effects model as obvious heterogeneity existed. No significant
29
30 associations were observed so far.
31
32
33
34
35
36
37
38
39

40 **Discussion**

41
42 Although osteoporosis isn't a deadly disease, it causes huge burden to individuals and
43
44 society owing to its high morbidity. Here, we got a comprehensive result by
45
46 meta-analysis, indicating that *H. pylori* infection may be a risk factor for osteoporosis.
47
48 However, the mechanism is still unclear. Several possible mechanisms may explain
49
50 this result. First, *H. pylori* infection may lead to systemic inflammation, and release of
51
52 cytokines, such as tumor necrosis factor-alpha, interleukin-1 and interleukin-6⁴⁵,
53
54 which may cause bone turnover indirectly. Second, many studies have shown that low
55
56
57
58
59
60

1
2
3
4 vitamin B12 may be associated with *H. pylori* infection⁴⁶. If the serum vitamin B12
5
6 levels are decreased, the folate becomes trapped as methyltetrahydrofolate and
7
8 interrupts for folate-related DNA synthesis, which is an important factor for bone
9
10 remodeling. Therefore, the decrease of vitamin B12 may lead to decreased BMD and
11
12 osteoporosis⁴⁷. Third, *H. pylori* infection may decrease the calcium absorption by
13
14 causing the gastric mucosal atrophy and decreasing acid secretion. Thus, eradication
15
16 of *H. pylori* may increase calcium absorption and stop the process of osteoporosis
17
18 through decreasing the levels of inflammatory cytokines and improving gastric
19
20 mucosal atrophy.
21
22
23
24
25

26
27 The present meta-analysis of 20 studies indicated that patients with *H. pylori* infection
28
29 were associated with an estimated 1.37 times higher odds ratios of developing
30
31 osteoporosis as compared with those without *H. pylori* infection, while no
32
33 associations were found in previous meta-analysis^{19 20} (one had 5 studies involving
34
35 1321 participants, and one had 4 studies involving 520 participants). As the previous
36
37 meta-analysis studies had no quality assessment and our analysis included more
38
39 studies and participants, the results in our study might be more reliable than the
40
41 previous meta-analysis studies.
42
43
44
45
46

47
48 Despite the significant association between *H. pylori* infection and osteoporosis,
49
50 obvious heterogeneity existed between the included studies. We found that sex of
51
52 participants may affect the results. As known to all, female and postmenopausal
53
54 women are independent risk factors of osteoporosis. Here, we explored the
55
56 relationship between osteoporosis and *H. pylori* infection, and found that the
57
58
59
60

1
2
3
4 relationship was significant in male, but not in female (whether postmenopausal or
5
6 not), which wasn't paradoxical with the fact that women with postmenopausal should
7
8 have a higher risk of osteoporosis than men. In the group of both sexes, the results
9
10 showed statistic difference and obvious heterogeneity, which may be due to the ratio
11
12 of M/F and other confounding factors. Therefore, we might suggest that more
13
14 attention should be paid to male than female in *H. pylori* positive patients. However,
15
16 only 7 studies (4 were about postmenopausal women and 3 were about
17
18 non-postmenopausal women) were conducted in female, the results may be not that
19
20 reliable due to the small sample size. Another reason may also be possible, that the
21
22 different degree of osteoporosis may affect the diagnosis and some early patients may
23
24 be regarded as healthy controls. Further studies with dose-response relationship of
25
26 different severity of osteoporosis and prevalence may help to confirm this hypothesis.
27
28 In the subgroup analysis by criteria (osteoporosis and osteopenia), the OR in
29
30 osteoporosis was a little higher than that in osteopenia, which may also help to prove
31
32 our hypothesis. In the subgroup analysis based on countries, significant association
33
34 was evidenced in three East-Asian countries (China, Japan and Korea are from East
35
36 Asia), indicating many other factors associated with geography may affect the results.
37
38 As only two studies were non-Asian countries, the reason of this phenomenon may be
39
40 due to the sample size, the same situations also happened in other Asian countries
41
42 with only one study included. In addition, as most studies included in our studies were
43
44 Asian countries, especially East Asia, whether our findings can be applied to other
45
46 populations around the world needs further exploring.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 In our research, we also explored the heterogeneity from diagnosis methods factors.
5
6 We found that the detection methods of osteoporosis (DEXA and quantitative
7
8 ultrasound) affected the pooled results, and the detection locations of DEXA also
9
10 contributed to the heterogeneity. From our results, we thought that DEXA might be a
11
12 better tool to diagnose osteoporosis in assessing the association between *H. pylori* and
13
14 osteoporosis. The same situation also happened in the detection methods of *H. pylori*.
15
16 We found ELISA and multi-method strategy may provide more homogeneous results.
17
18 In total, in despite of the significant association between *H. pylori* and osteoporosis,
19
20 as the heterogeneity still existed obviously, further studies were still needed to address
21
22 its potential confounding factors.
23
24
25
26
27
28

29
30 In a previous meta-analysis study, Karn Wijarnpreecha et al found increased odds of
31
32 nonalcoholic fatty liver disease (NAFLD) among patients infected with *H. pylori*⁴⁸.
33
34 However, Sikarin Upala et al found that no significant difference in BMD between
35
36 patients with fatty liver disease and controls⁴⁹. Combine the two meta-analysis and
37
38 our results, we may guess that *H. pylori* may be an independent risk factor of NAFLD
39
40 and osteoporosis, and/or *H. pylori* infection may be an important confounding factor
41
42 in exploring the relationship between NAFLD and osteoporosis, or no actual
43
44 relationship between NAFLD and osteoporosis exists. However, as the authors
45
46 stated⁴⁹, the review was a preliminary result because of limited amount of literature, it
47
48 might be too early to have definite conclusion.
49
50
51
52
53

54 We also compared the quantitative alterations of BMD in *H. pylori* infected subjects.
55
56 However, no significant difference was found. The reason may be that: 1) the sample
57
58
59
60

1
2
3
4 size was relatively small, 2) the severities of *H. pylori* infection were not serious, or
5
6 the infection of *H. pylori* didn't last long enough to cause alterations, 3) though the
7
8 basic characteristics of included studies were comparable, many other confounding
9
10 factors that might affect BMD have not been adjusted. Therefore, more studies with
11
12 large sample size were still needed to verify the alterations of BMD in *H. pylori*
13
14 infection.
15
16
17
18

19 The strength of the present meta-analysis lies in inclusion of 21 observational studies
20
21 reporting data on *H. pylori* infection and osteoporosis, and the alterations of BMD by
22
23 *H. pylori*. However, our meta-analysis has several limitations that should be
24
25 recognized when interpreting the results. First, most of the included studies were
26
27 hospital-based or health center-based, which were not affected by detection bias, but
28
29 might be subjected to selection bias. However, the prevalence of *H. pylori* infection in
30
31 most studies that we selected was consistent with the incidence rate in the general
32
33 population. Second, our analysis had an ascertainment bias that might be present
34
35 because progression of osteoporosis is continuous, and some patients may be
36
37 classified as controls. However, this may lead to a more conservative result, which
38
39 may help to indicate that our overall result is reliable. Third, the heterogeneity is still
40
41 obvious. However, we performed subgroup analyses based on study characteristics,
42
43 and found that some factors may affect the association. In addition, when available,
44
45 adjusted estimates were used in preference to unadjusted estimates. Even though the
46
47 adjusted estimates may be closer to the true effect for adjusted results could control
48
49 confounding factors^{50 51}, the different adjusted factors in different studies may also
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 contribute to the heterogeneity. Four, the qualities of included studies were medium,
5
6 and some studies were published informally. We also included all these studies based
7
8 on inclusion and exclusion criteria to avoid publication bias. Nevertheless, our study
9
10 is still the most comprehensive about the association between *H. pylori* infection and
11
12 osteoporosis.
13
14

15
16
17 In summary, our results suggest significant increased odds of osteoporosis in patients
18
19 with *H. pylori* infection. The clinicians should pay more attentions to the patients
20
21 infected with *H. pylori* by using DEXA scan, especially those chronic gastritis
22
23 patients. However, the results should be cautiously interpreted considering the
24
25 heterogeneity and the fact that all studies are non-randomized and retrospective.
26
27 Further studies are needed to explore the mechanism and confounding factors
28
29 between *H. pylori* and osteoporosis.
30
31
32
33
34
35
36
37

38 **Funding**

39
40 This work was supported by the National Natural Science Foundation of China [No.
41
42 81202220 to Y. Z.; No. 81673211 and 81372952 to T. C.], by the Natural Science
43
44 Foundation of Jiangsu Province, China [No. BK20150094 to Q.Z.], and by the
45
46 Chongqing Health and Family Planning Commission [No. 20141027 to H. X.].
47
48
49

50 **Contributors**

51
52
53 YZ and HX led the study by designing, interpreting results, and revising manuscript
54
55 critically for important intellectual content; TW and XL contributed to data analysis,
56
57 result interpretation and drafting of the manuscript; QZ, BG and JZ participated in
58
59
60

1
2
3
4 study data collection and revising manuscript; TW, XL, TC and LY participated in
5
6 study conduct and results interpretation. All authors read and approved the final
7
8 manuscript.
9

10 11 **Competing interests**

12
13
14 The authors declare that they have no competing interests.
15

16
17 **Patient consent** Not required.
18

19
20 **Provenance and peer review** Not commissioned; externally peer reviewed.
21

22
23 **Data sharing statement** No additional data are available.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Zeng MD, Fan JG, Lu LG, et al. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. *J Dig Dis* 2008;9(2):108-12. doi: 10.1111/j.1751-2980.2008.00331.x [published Online First: 2008/04/19]
2. Lu L-j, Hao N-B, Liu J-J, et al. Correlation between Helicobacter pylori Infection and Metabolic Abnormality in General Population: A Cross-Sectional Study. *Gastroenterology research and practice* 2018
3. Ozaydin N, Turkyilmaz SA, Cali S. Prevalence and risk factors of Helicobacter pylori in Turkey: a nationally-representative, cross-sectional, screening with the (1)(3)C-Urea breath test. *BMC public health* 2013;13:1215. doi: 10.1186/1471-2458-13-1215 [published Online First: 2013/12/24]
4. Dorji D, Dendup T, Malaty HM, et al. Epidemiology of Helicobacter pylori in Bhutan: the role of environment and Geographic location. *Helicobacter* 2014;19(1):69-73. doi: 10.1111/hel.12088 [published Online First: 2013/10/10]
5. Eusebi LH, Zagari RM, Bazzoli F. Epidemiology of Helicobacter pylori infection. *Helicobacter* 2014;19 Suppl 1:1-5. doi: 10.1111/hel.12165 [published Online First: 2014/08/30]
6. den Hollander WJ, Holster IL, den Hoed CM, et al. Ethnicity is a strong predictor for Helicobacter pylori infection in young women in a multi-ethnic European city. *J Gastroenterol Hepatol* 2013;28(11):1705-11. doi: 10.1111/jgh.12315 [published Online First: 2013/07/03]
7. Pereira MI, Medeiros JA. Role of Helicobacter pylori in gastric mucosa-associated lymphoid tissue lymphomas. *World journal of gastroenterology* 2014;20(3):684-98. doi: 10.3748/wjg.v20.i3.684 [published Online First: 2014/02/28]
8. Bellos I, Daskalakis G, Pergialiotis V. Helicobacter pylori infection increases the risk of developing preeclampsia: A meta-analysis of observational studies. *Int J Clin Pract* 2018;72(2) doi: 10.1111/ijcp.13064 [published Online First: 2018/02/02]
9. Hou Y, Sun W, Zhang C, et al. Meta-analysis of the correlation between Helicobacter pylori infection and autoimmune thyroid diseases. *Oncotarget* 2017;8(70):115691-700. doi: 10.18632/oncotarget.22929 [published Online First: 2018/02/01]
10. Rahmani Y, Mohammadi S, Babanejad M, et al. Association of Helicobacter Pylori with Presence of Myocardial Infarction in Iran: A Systematic Review and Meta-Analysis. *Ethiopian journal of health sciences* 2017;27(4):433-40. [published Online First: 2017/12/09]
11. Wijarnpreecha K, Chesdachai S, Thongprayoon C, et al. Association of Helicobacter pylori with the Risk of Hepatic Encephalopathy. *Digestive diseases and sciences* 2017;62(12):3614-21. doi: 10.1007/s10620-017-4834-1 [published Online First: 2017/11/10]
12. Abdollahi A, Etemadian M, Shoar S, et al. Is Helicobacter pylori Infection a Risk Factor for Prostatitis? A Case-Control Study in a Referring Tertiary Care Center. *Iranian journal of pathology* 2016;11(4):323-27. [published Online First: 2017/09/01]
13. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. *The American journal of medicine* 1993;94(6):646-50. [published Online First: 1993/06/01]
14. Wu TY, Hu HY, Lin SY, et al. Trends in hip fracture rates in Taiwan: a nationwide study from 1996 to 2010. *Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA* 2017;28(2):653-65. doi: 10.1007/s00198-016-3783-4 [published Online First:

- 2016/11/20]
15. Hernlund E, Svedbom A, Ivergard M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). *Arch Osteoporos* 2013;8:136. doi: 10.1007/s11657-013-0136-1 [published Online First: 2013/10/12]
 16. Asaoka D, Nagahara A, Shimada Y, et al. Risk factors for osteoporosis in Japan: Is it associated with *Helicobacter pylori*? *Therapeutics and clinical risk management* 2015;11((Asaoka D., daisuke@juntendo.ac.jp; Nagahara A.; Shimada Y.; Matsumoto K.; Ueyama H.; Matsumoto K.; Nakagawa Y.; Takeda T.; Tanaka I.; Sasaki H.; Osada T.; Hojo M.; Watanabe S.) Department of gastroenterology, University of Juntendo, School of Medicine, Tokyo, Japan):381-91. doi: 10.2147/tcrm.s80647
 17. Yoshimura N, Suzuki T, Hosoi T, et al. Epidemiology of hip fracture in Japan: incidence and risk factors. *Journal of bone and mineral metabolism* 2005;23 Suppl:78-80. [published Online First: 2005/06/30]
 18. Liu K, Liu P, Liu R, et al. Relationship between serum leptin levels and bone mineral density: a systematic review and meta-analysis. *Clinica chimica acta; international journal of clinical chemistry* 2015;444:260-3. doi: 10.1016/j.cca.2015.02.040 [published Online First: 2015/03/10]
 19. Upala S, Sanguankeo A, Wijarnpreecha K, et al. Association between *Helicobacter pylori* infection and osteoporosis: a systematic review and meta-analysis. *Journal of bone and mineral metabolism* 2016;34(4):482-3. doi: 10.1007/s00774-015-0703-1 [published Online First: 2015/08/22]
 20. Jaruvongvanich V, Upala S, Wijarnpreecha K, et al. Association between *helicobacter pylori* and osteoporosis: A systematic review and meta-analysis. *American Journal of Gastroenterology* 2015;110((Jaruvongvanich V.) University of Hawaii, Internal Medicine Residency Program, John A. Burns School of Medicine, Honolulu, HI, United States):S1021. doi: 10.1038/ajg.2015.281
 21. Chinda D, Shimoyama T, Matsuzaka M, et al. *Helicobacter pylori* infection is not a risk for osteopenia in Japanese healthy males. *American Journal of Gastroenterology* 2016;111((Chinda D.; Shimoyama T.; Fukuda S.) Department of Gastroenterology, Hirosaki University, Graduate School of Medicine, Hirosaki, Aomori, Japan):S1289. doi: 10.1038/ajg.2016.390
 22. Chinda D, Shimoyama T, Matsuzaka M, et al. Decrease of estradiol and several life style factors, but not *helicobacter pylori* infection, are significant risks for osteopenia in Japanese females. *American Journal of Gastroenterology* 2016;111((Chinda D.; Shimoyama T.; Fukuda S.) Department of Gastroenterology, Hirosaki University, Graduate School of Medicine, Hirosaki, Aomori, Japan):S499. doi: 10.1038/ajg.2016.363
 23. Kalantarhormozi MR, Assadi M, Vahdat K, et al. *Chlamydia pneumoniae* and *Helicobacter pylori* IgG seropositivities are not predictors of osteoporosis-associated bone loss: a prospective cohort study. *Journal of bone and mineral metabolism* 2016;34(4):422-28. doi: 10.1007/s00774-015-0688-9
 24. Zhang C, Guo L, Hou W, et al. Relationship between the interaction of gastric *helicobacter pylori* infection and polymorphism of TLR4 gene G11367C and NADPH oxidase gene His72Tyr and

- 1
2
3 the idiopathic osteoporosis in adults. *Chinese Journal of Osteoporosis* 2016;22(5):515-23.
- 4
5 25. Abdolahi N, Aghaei M, Naghdi M. Helicobacter pylori infection and osteoporosis in post
6 monopausal women. *Annals of the Rheumatic Diseases* 2017;76((Abdolahi N.; Aghaei M.;
7 Naghdi M.) Golestan Rheumatology Research Center, Golestan University of Medical
8 Sciences, Gorgan, Iran):1354. doi: 10.1136/annrheumdis-2017-eular.6445
- 9
10 26. Chinda D, Shimoyama T, Iino C, et al. Decrease of Estradiol and Several Lifestyle Factors, but Not
11 Helicobacter pylori Infection, Are Significant Risks for Osteopenia in Japanese Females.
12 *Digestion* 2017;96(2):103-09. doi: 10.1159/000479317
- 13
14 27. Pan BL, Huang CF, Chuah SK, et al. Relationship between Helicobacter pylori infection and bone
15 mineral density: a retrospective cross-sectional study. *BMC Gastroenterol* 2018;18(1):54. doi:
16 10.1186/s12876-018-0780-4 [published Online First: 2018/04/28]
- 17
18 28. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and
19 meta-analyses: the PRISMA statement. *PLoS Med* 2009;6(7):e1000097. doi:
20 10.1371/journal.pmed.1000097 [published Online First: 2009/07/22]
- 21
22 29. Wright E, Schofield PT, Molokhia M. Bisphosphonates and evidence for association with
23 esophageal and gastric cancer: a systematic review and meta-analysis. *BMJ open*
24 2015;5(12):e007133. doi: 10.1136/bmjopen-2014-007133 [published Online First:
25 2015/12/09]
- 26
27 30. Ottawa Hospital Research Institute, "The Newcastle-Ottawa Scale (NOS) for assessing the quality
28 of nonrandomized studies in meta-analyses," 2011, <http://www.ohri.ca/programs/clinical>
29 [epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical).
- 30
31 31. Deeks JJ, Higgins JP, Altman DG, et al. Analysing data and undertaking meta-analysis; in Higgins JP
32 (ed.): *Cochrane Handbook for systematic Reviews of Interventions*. Chichester, The Cochrane
33 Collaboration 2008: 243–296
- 34
35 32. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical
36 test. *BMJ* 1997;315(7109):629-34. [published Online First: 1997/10/06]
- 37
38 33. Mizuno S, Matsui D, Watanabe I, et al. Serologically Determined Gastric Mucosal Condition Is a
39 Predictive Factor for Osteoporosis in Japanese Men. *Digestive diseases and sciences*
40 2015;60(7):2063-69. doi: 10.1007/s10620-015-3576-1
- 41
42 34. Fotouk-Kiai M, Hoseini SR, Meftah N, et al. Relationship between Helicobacter pylori infection (HP)
43 and bone mineral density (BMD) in elderly people. *Caspian journal of internal medicine*
44 2015;6(2):62-66.
- 45
46 35. Chung YH, Gwak JS, Hong SW, et al. Helicobacter pylori: A Possible Risk Factor for Bone Health.
47 *Korean journal of family medicine* 2015;36(5):239-44. doi: 10.4082/kjfm.2015.36.5.239
48 [published Online First: 2015/10/06]
- 49
50 36. Asaoka D, Nagahara A, Shimada Y, et al. Risk factors for osteoporosis-are infection or eradication
51 of helicobacter pylori associated? *Gastroenterology* 2015;148(4):S337-S38.
- 52
53 37. Lin SC, Koo M, Tsai KW. Association between helicobacter pylori infection and risk of osteoporosis
54 in elderly Taiwanese women with upper gastrointestinal diseases: A retrospective patient
55 record review. *Gastroenterology research and practice* 2014;2014((Lin S.-C.,
56 t780927t@yahoo.com.tw; Tsai K.-W., cksai@aol.com) Department of Geriatrics, Dalin Tzu
57 Chi Hospital, Buddhist Tzu Chi Medical Foundation, 2 Minsheng Road, Dalin, Chiayi 62247,
58 Taiwan) doi: 10.1155/2014/814756
- 59
60 38. Asaoka D, Nagahara A, Shimada Y, et al. H.pylori infection is a risk factor of osteoporosis in Japan.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Gastroenterology* 2014;146(5):S-504. doi: 10.1016/s0016-5085(14)61821-7
39. Asaoka D, Nagahara A, Hojo M, et al. The Relationship between H-pylori Infection and Osteoporosis in Japan. *Gastroenterology research and practice* 2014
40. Chinda D, Shimoyama T, Matsuzaka M, et al. Assessment of the association between helicobacter pylori infection and osteopenia in japanese healthy adults. *Helicobacter* 2013;18((Chinda D.; Shimoyama T.; Matsuzaka M.; Nakaji S.; Fukuda S.) Hirosaki University Graduate, School of Medicine, Hirosaki, Japan):114. doi: 10.1111/hel.12079
41. Akkaya N, Akkaya S, Polat Y, et al. Helicobacter Pylori Seropositivity in Patients with Postmenopausal Osteoporosis. *Journal of Physical Therapy Science* 2011;23(1):61-64.
42. Kakehasi AM, Rodrigues CB, Carvalho AV, et al. Chronic gastritis and bone mineral density in women. *Digestive diseases and sciences* 2009;54(4):819-24. doi: 10.1007/s10620-008-0417-5 [published Online First: 2008/08/08]
43. Kakehasi AM, Mendes CMC, Coelho LGV, et al. The presence of Helicobacter pylori in postmenopausal women is not a factor to the decrease of bone mineral density. *Arquivos de gastroenterologia* 2007;44(3):266-70.
44. Figura N, Gennari L, Merlotti D, et al. Prevalence of Helicobacter pylori infection in male patients with osteoporosis and controls. *Digestive diseases and sciences* 2005;50(5):847-52. doi: 10.1007/s10620-005-2651-4
45. Noach LA, Bosma NB, Jansen J, et al. Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. *Scand J Gastroenterol* 1994;29(5):425-9. [published Online First: 1994/05/01]
46. Kalkan C, Karakaya F, Tuzun A, et al. Factors related to low serum vitamin B12 levels in elderly patients with non-atrophic gastritis in contrast to patients with normal vitamin B12 levels. *Geriatrics & gerontology international* 2016;16(6):686-92. doi: 10.1111/ggi.12537 [published Online First: 2015/06/06]
47. Tucker KL, Hannan MT, Qiao N, et al. Low plasma vitamin B12 is associated with lower BMD: the Framingham Osteoporosis Study. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research* 2005;20(1):152-8. doi: 10.1359/JBMR.041018 [published Online First: 2004/12/28]
48. Wijarnpreecha K, Thongprayoon C, Panjawan P, et al. Helicobacter pylori and Risk of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. *Journal of clinical gastroenterology* 2018;52(5):386-91. doi: 10.1097/MCG.0000000000000784 [published Online First: 2017/01/19]
49. Upala S, Jaruvongvanich V, Wijarnpreecha K, et al. Nonalcoholic fatty liver disease and osteoporosis: a systematic review and meta-analysis. *Journal of bone and mineral metabolism* 2017;35(6):685-93. doi: 10.1007/s00774-016-0807-2 [published Online First: 2016/12/09]
50. Luo Y, Bao X, Zheng S, et al. A potential risk factor of essential hypertension in case-control study: MicroRNAs miR-10a-5p. *Clin Exp Hypertens* 2019:1-7. doi: 10.1080/10641963.2019.1571597 [published Online First: 2019/02/02]
51. Yan S, Sun R, Wu S, et al. Single nucleotide polymorphism in the 3' untranslated region of LPP is a risk factor for lung cancer: a case-control study. *BMC cancer* 2019;19(1):35. doi: 10.1186/s12885-018-5241-5 [published Online First: 2019/01/10]

1
2
3
4 Figure legend
5
6
7
8

9 Figure 1. Flow diagram of the article selection for systematic review.
10

11 Figure 2. Forest plot of the included studies assessing the association between
12 *Helicobacter pylori* and osteoporosis (random effects models). CI indicates
13 confidence interval.
14
15
16
17
18

19 Figure 3. Forest plot of cumulative meta-analysis.
20

21 Figure 4. Forest plot of subgroup meta-analysis according to diagnosis (random
22 effects models).
23
24
25

26 Figure 5. Funnel plot of publication bias for the association between *Helicobacter*
27 *pylori* and osteoporosis.
28
29
30
31

32 Figure 6. The Egger's test for publication bias.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Characteristics and quality assessment of the studies included

| Author [Reference] | Year | Country | Sex(M/F) | Age(mean age±SD or (range age) years) | Detection method of <i>H.pylori</i> | Detection methods of osteoporosis | Diagnosis locations | Diagnosis | Cases/Controls/ Total | Scores of NOS | Main adjusted factors (the methods used for adjusting) |
|-------------------------------------|------|---------|----------------------|--|-------------------------------------|-----------------------------------|-----------------------|--------------|-----------------------|---------------|---|
| Figura, N. ⁴⁴ | 2005 | Italy | Males | 65 (55–82) for patients; 64.5(55–80) for controls | ELISA | DEXA | Lumbar and femur bone | Osteoporosis | 80/160/240 | 7 | age, socioeconomic background, and smoking habits. |
| Adriana M. KAKEHASI ⁴³ | 2007 | Brazil | Postmenopausal women | 61.6±7(50–79) | non-ELISA | DEXA | Lumbar spine | Osteoporosis | 18/32/50 | 6 | mean age, body mass index, age at menarche, postmenopausal period |
| Adriana M. Kakehasi ^{42,#} | 2009 | Brazil | Postmenopausal women | 63.7±7.3 for Hp(+) 62.5±7.0 for Hp(-) | non-ELISA | DEXA | Lumbar spine and hip | Not fitted* | 34/27/61 | - | age, Postmenopausal time, BMI |
| Akkaya, Nuray ⁴¹ | 2011 | Turkey | Postmenopausal women | 65.29±6.09 patients; 63.57±6.53 controls | ELISA | DEXA | Lumbar and femur neck | Osteoporosis | 58/47/105 | 6 | age, education level, occupation, age of menarche or menopause, duration of postmenopausal, period or daily consumption of tea, coffee, alcohol or dairy products |
| Chinda, D. ⁴⁰ | 2013 | Japan | 379/631 | not mentioned | ELISA | QU | Calcaneal osteo | Osteopenia | -/-/1010 | 7 | age, BMI, smoking, alcohol consumption, periodical exercise, latest educational level (logistic regression analysis) |
| Asaoka, Daisuke ³⁹ | 2014 | Japan | 95/105 | 63.1±8.8 years | Both | DEXA | Lumbar vertebrae | Osteoporosis | 41/159/200 | 6 | age, gender, BMI, alcohol consumption, smoking, BAP, PUD, and EGA (multivariate logistic regression analysis) |
| Asaoka, D. ³⁸ | 2014 | Japan | 131/26 | 71.1±7.5 patients 61.6±8.9 controls | not mentioned | DEXA | Lumbar | Osteoporosis | 24/133/157 | 6 | age, sex, BMI, Brinkman Index (B.I.), accumulated amount of alcohol (multivariate analysis) |
| Lin, S. C. ³⁷ | 2014 | China | Female | 77 (65–97) | non-ELISA | DEXA | Not mentioned | Osteoporosis | 101/264/365 | 5 | age group, body mass index group, and use of proton pump inhibitor (multivariate logistic regression analyses) |
| Asaoka, D. ³⁶ | 2015 | Japan | 130/134 | 69.8±6.8 for patients 61.9±8.2 for controls | not mentioned | DEXA | Not mentioned | Osteoporosis | 45/219/264 | 7 | age, sex, BMI. etc (multivariate analysis) |
| Asaoka, D. ¹⁶ | 2015 | Japan | 120/135 | 63.2±8.5 | Both | DEXA | Lumbar vertebrae | Osteoporosis | 43/212/255 | 6 | age, sex, BMI, cumulative alcohol intake, Brinkman index, type 2 diabetes mellitus, calcium channel blocker, PPI, hemoglobin, calcium, gamma glutamyl transpeptidase, bone-specific alkaline phosphatase, NTX, hiatal hernia, and EGA (multivariate logistic regression analysis) |
| Chung, Y. H. ^{35,#} | 2015 | Korea | Men | 54.4±10.7 for Hp+ 51.9±12.1 for Hp- | ELISA | DEXA | Lumbar (L1–L4) | osteopenia | -/-/1126 | 7 | Height, weight, BMI, alcohol, exercise. |
| Fotouk-Kiai, M. ^{34,#} | 2015 | Iran | 575/392 | 68.3±6.8 for hp+ 69.3±7.4 for hp- | ELISA | DEXA | Lumbar vertebra | Osteoporosis | 314/653/967 | 5 | age, sex, smoking, alcohol consumption and BMI |

| 1 | | | | | | | | | | | | |
|----|--|------|----------|----------------------|---|-----------|---------------|------------------------|---------------|--------------|---|--|
| 2 | | | | | | | | | | | | |
| 3 | Mizuno, S. ³³ | 2015 | Japanese | Men | 62.1±5.0 for low TBD 58.4±5.7 for normal | ELISA | QU | Not mentioned | Decreased BMD | 116/114/230 | 8 | Age, BMI and smoking habit (logistic regression analysis) |
| 4 | | | | | | | | | | | | |
| 5 | | | | | | | | | | | | |
| 6 | Chinda, D. ²¹ | 2016 | Japan | Men | 50.2±15.4 years | ELISA | QU | Not mentioned | Osteopenia | -/-/295 | 7 | age, BMI, serum level of estradiol, the intake of calcium per day, smoking, drinking, periodical exercise, last educational background (logistic regression) |
| 7 | | | | | | | | | | | | |
| 8 | | | | | | | | | | | | |
| 9 | | | | | | | | | | | | |
| 10 | Chinda, D. ²² | 2016 | Japan | Females | 52.2±15.2 | ELISA | QU | Not mentioned | Osteopenia | -/-/473 | 6 | age, BMI, smoking, alcohol consumption, periodical exercise, last educational level, serum level of estradiol, calcium intake per day (multiple logistic regression) |
| 11 | | | | | | | | | | | | |
| 12 | | | | | | | | | | | | |
| 13 | Kalantarhormozi, M. R. ^{23,#} | 2016 | Iran | Postmenopausal women | 58.87±8.02 | ELISA | DEXA | lumbar spine and femur | Osteoporosis | 16/234/250 | 6 | age and BMI (multiple linear regression) |
| 14 | | | | | | | | | | | | |
| 15 | | | | | | | | | | | | |
| 16 | Zhang, Chaoxian ²⁴ | 2016 | China | 194/126 | 38.32±10.64 for patients 38.27±7.46 for controls | non-ELISA | DEXA | Not mentioned | Osteoporosis | 160/160/320 | 5 | Age, gender, gene (multiple logistic regression) |
| 17 | | | | | | | | | | | | |
| 18 | | | | | | | | | | | | |
| 19 | Abdolahi, N. ²⁵ | 2017 | Iran | Postmenopausal women | not mentioned | ELISA | not mentioned | Not mentioned | Osteoporosis | 73/34/107 | 8 | not mentioned |
| 20 | | | | | | | | | | | | |
| 21 | | | | | | | | | | | | |
| 22 | Chinda, D. ²⁶ | 2017 | Japan | Females | 62.5±8.6 for patients 44.9±10.9 for controls | ELISA | QU | Calcaneus | Osteopenia | 197/276/473 | 4 | age, smoking and drinking habit, schooling duration, estradiol levels, menopause, birth history (multiple logistic regression analysis) |
| 23 | | | | | | | | | | | | |
| 24 | | | | | | | | | | | | |
| 25 | Lu, Li-juan ² | 2018 | China | 1474/393 | 54.0±9.6 | non-ELISA | QU | Calcaneus | Osteoporosis | 900/967/1867 | 6 | gender and age |
| 26 | | | | | | | | | | | | |
| 27 | | | | | | | | | | | | |
| 28 | Pan, B. L. ²⁷ | 2018 | China | 568/299 | 55.9±11.3 | non-ELISA | DEXA | Not mentioned | Decreased BMD | 311/556/867 | 5 | Sex, age, BMI, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and peptic ulcer disease (multiple stepwise logistic regression analyses) |
| 29 | | | | | | | | | | | | |
| 30 | | | | | | | | | | | | |

31

32 Not fitted *: this study only explored the alteration of BMD in patients with *H. pylori* infection.

33

34 #: this study also reported the BMD in patients with *H. pylori* infection.

35

36 ELISA: enzyme linked immunosorbent assay; QU: quantitative ultrasound; DEXA: dual energy X-ray absorptiometry scan; NOS : Newcastle-Ottawa scale

37

38

39

40

41

42

43

44

45

46

Table 2. Overall effect estimates for *Helicobacter pylori* infection and osteoporosis according to study characteristics

| Factors | Categories | No. of studies | OR [95%CI] | Model used | Heterogeneity | | Meta-regression | |
|---------------------------------------|--------------------------|----------------|------------------|------------|----------------|---------|-----------------|---------|
| | | | | | I ² | P-value | t | P-value |
| Sex* | | | | | | | | |
| | Female | 8 | 1.09(0.87,1.35) | Fixed | 33.0% | 0.17 | - | - |
| | Male | 5 | 1.27(1.07,1.50) | Fixed | 14.6% | 0.32 | 0.47 | 0.64 |
| | Both | 9 | 1.21(1.07,1.37) | Random | 85.6% | 0.00 | 1.78 | 0.09 |
| Postmenopausal or not | | | | | | | | |
| | Non-postmenopausal women | 4 | 1.08 (0.83,1.41) | Fixed | 48.0% | 0.12 | - | - |
| | Postmenopausal women | 4 | 1.09(0.75,1.58) | Fixed | 35.8% | 0.20 | -0.13 | 0.90 |
| Country | | | | | | | | |
| | China | 4 | 1.86(1.06,3.28) | Random | 90.4% | 0.00 | - | - |
| | Japan | 9 | 1.57(1.08,2.28) | Random | 63.7% | 0.005 | -0.39 | 0.70 |
| | Italy | 1 | 0.87(0.50,1.53) | | - | - | -1.11 | 0.29 |
| | Brazil | 1 | 0.42(0.12,1.42) | | - | - | -1.69 | 0.11 |
| | Korea | 1 | 1.29(1.05,1.57) | | - | - | -0.59 | 0.57 |
| | Iran | 3 | 1.06(0.60,1.86) | Random | 61.3% | 0.075 | -1.16 | 0.27 |
| | Turkey | 1 | 0.95(0.53,1.69) | | - | - | -0.98 | 0.34 |
| Asian country or not | | | | | | | | |
| | Non-Asian country | 2 | 0.77(0.46,1.28) | Fixed | 12.8% | 0.28 | - | - |
| | Asian country | 18 | 1.44(1.16,1.79) | Random | 73.9% | 0.00 | 1.60 | 0.13 |
| Detection methods of <i>H. pylori</i> | | | | | | | | |
| | ELISA | 11 | 1.09(0.96,1.24) | Fixed | 32.1% | 0.14 | - | - |
| | Non-ELISA | 5 | 1.62(0.96,2.72) | Random | 88.4% | 0.00 | 1.52 | 0.15 |
| | Both | 2 | 3.67(1.88, 7.16) | Fixed | 0% | 0.42 | 2.65 | 0.02 |
| Detection methods of osteoporosis | | | | | | | | |
| | DEXA | 13 | 1.58(1.14,2.18) | Random | 79.5% | 0.00 | - | - |
| | QU | 6 | 1.05(0.90,1.22) | Fixed | 0% | 0.51 | -1.33 | 0.20 |
| Detection location of DEXA | | | | | | | | |

| | | | | | | | | |
|--|--------|---|-----------------|--------|-------|-------|-------|------|
| | Lumbar | 6 | 1.75(0.99,3.07) | Random | 65.4% | 0.013 | - | - |
| | Femur | 3 | 1.56(1.17,2.08) | Fixed | 0% | 0.90 | -0.17 | 0.87 |

*: One study has both males, females and over results, it was used three times in subgroups analysis (males, females, and both).

ELISA: enzyme linked immunosorbent assay; QU: quantitative ultrasound; DEXA: dual energy X-ray absorptiometry scan.

For peer review only




Fig 1

199x194mm (300 x 300 DPI)




Fig 2

279x228mm (300 x 300 DPI)




Fig 3

281x240mm (300 x 300 DPI)




Fig 4

282x248mm (300 x 300 DPI)




Fig 5

79x60mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Fig 6

152x101mm (300 x 300 DPI)

1
2
3
4 The search string for our study:
5

6 The search strategy for H. pylori were “((helicobacter pylori) OR (campylobacter
7 pylori) OR (H. pylori) OR (h. pylori) OR hp OR helicobacter OR (helicobacter bill)
8 OR (helicobacter hepaticus) OR (helicobacter pullorum) OR (h. bilis) OR (h.
9 hepaticus) OR (h. pullorum) OR (h. ganmam) OR (helicobacter species) OR
10 (helicobacter sp) OR (helicobacter genus) OR campylobacter OR (campylobacter
11 infection) OR campylobacteriosis OR (helicobacter pylori infection) OR (helicobacter
12 infection) OR (pylori) OR (enterohepatic helicobacter spp) OR (campylobacter spp)),
13 the search strategy for osteoporosis were (“fragility fracture” OR “Bone Density”
14 [MeSH] OR “bone density” OR “bone mass density” OR “Osteocalcin” [MeSH] OR
15 “bone loss” OR “Osteoporosis” OR “Osteoporosis” [MeSH]”. Finally, we used
16 “AND” to pool these results.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Meta-analysis of SMD according to detection locations.